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ABSTRACT 
Spermatogonial stem cells (SSCs), the foundational cells of 
spermatogenesis, are maintained through the delicate balance of self re-newel or 
proliferation and differentiation. The growth factor glial cell line-derived 
neurotrophic factor (GDNF) has been shown to be critical in establishing this pool 
in the prepubertal animal, but its in vivo function in the normal adult testis has yet 
to be elucidated. We used a unique in vivo chemical-genetic approach to test the 
hypothesis that GDNF was essential in regulating stem and progenitor 
spermatogonia in the normal adult mouse. Using this experimental strategy, we 
were able to reversibly inhibit GDNF signaling for acute (2-3 days), intermediate 
(11 days) and prolonged (30 days) periods of time. Our results showed that this 
inhibition led to a progressive loss of cells expressing spermatogonial stem cell 
markers and transcripts. Taken together, we interpret these decreases as a loss 
of spermatogonial stem cells and/or progenitor spermatogonia. This 
interpretation is supported by the fact that all spermatogenic cells, including 
spermatogonia, were lost by maturation depletion after prolonged inhibition of 
GDNF signaling.  These results are the first to provide direct evidence that GDNF 
regulates the numbers of spermatogonial stem cells in vivo, in the normal adult 
testis.  
Based on our observations in the mouse and the striking similarity in 
spermatogenesis between rodents and humans, we hypothesized that this 
growth factor has a similar function in men. Specifically, we hypothesized that 
GDNF expression would be similar in the testes of normal men, when compared 
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to mice and rats, whose SSCs are GDNF-dependent. Our results show that 
GDNF mRNA levels in mice and men are almost identical. We also observed that 
the level of GDNF protein in rat total testicular fluid is identical to humans. These 
data suggest that GDNF could be essential in regulating human SSCs and 
progenitor spermatogonia. To further test this hypothesis, we compared GDNF 
mRNA levels in normal human testes with levels in testes of men who were 
diagnosed as being infertile due to the lack of spermatogenic cells, resulting in 
maturation arrest or a Sertoli cell-only (SCO) phenotype. Our results showed that 
there was an 80% decrease in GDNF mRNA expression in testes exhibiting the 
later phenotype, but not in testes with maturation arrest of spermatogenesis. To 
address whether this reduced expression in infertile individuals with the SCO 
phenotype was due to a complete state of hypo-function or a specific deficiency 
in their Sertoli cells, we measured transcripts encoding two other Sertoi cell 
products, Kit ligand and Clusterin. Expression of neither transcript was reduced 
in these SCO testes. Taken together, our data support the hypothesis that as in 
rodents, GDNF is essential for maintaining and regulating human SSCs and 
progenitor spermatogonia. These findings provide strong evidence that 
decreased GDNF expression may lead to the loss of SSCs, and consequently to 
human male infertility. Our results open up a new area of research geared 
towards clinical intervention using therapeutics to increase GDNF concentration 
in individuals with SCO testes with a few remaining SSCs. The use of such 
therapeutics might aid in rebuilding the numbers of these stem cells and increase 
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CHAPTER 1: LITERATURE REVIEW 
 
Introduction: 
The delicate nature of male fertility depends on the proper function of 
spermatogonial stem cells (SSCs). Extensive research using rodent models 
identifies glial cell-line derived neurotrophic factor (GDNF) as an essential 
regulator of the numbers of SSCs both in vivo and in vitro. From these studies, 
we know that in vivo GDNF over expression results in the formation of clusters of 
undifferentiated spermatogonia, which are eliminated by apoptosis, resulting in 
infertile mice [1]. Conversely, testes of GDNF null mice are devoid of most all 
germ cells within 7 days, and the few remaining germ cells do not replicate [2]. 
Mice haploinsufficient for GDNF also show a progressive loss of spermatogonia, 
spermatocytes and spermatids, resulting in a lack of germ cells in mature mice 
[1]. While informative, these studies demonstrate that GDNF is essential for 
establishing the stem spermatogonial pool in the context of an immature mouse 
testis. Prior to the studies described in this dissertation, the effects of the loss of 
GDNF signaling and the consequences of restoration of this signaling in the 
normal adult mouse testis have not been elucidated, and thus, proves to be a 
significant gap in our knowledge. In humans, the potential role of GDNF in the 
regulation of human SSCs is limited to the knowledge that Sertoli cells 
transcriptionally express GDNF [3]. Thus, defining the role of GDNF in the human 
testicular environment, and determining whether it is essential to the regulation of 
spermatogonial stem cells and progenitor spermatogonia is necessary to 
furthering our understanding of human male fertility. The studies outlined in this 
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thesis are an attempt to address these gaps in our knowledge about the role of 
GDNF in regulating numbers of SSCs in normal adult mice and men. Our results 
provide important evidence that GDNF concentration in the human testis is 
sufficient to regulate SSC and progenitor spermatogonia, as shown in the mouse. 
Furthermore, we demonstrate that GDNF expression is substantially reduced in a 
subset of men diagnosed with non-obstructive azoospermia. These results have 
important implications in understating the cause of infertility in a subset of infertile 
men. The long-term goal of these studies is to translate our findings into the clinic 
as a mode of growth hormone based therapy for a sub-population of infertile 
patients, where infertility stems from insufficient stimulation of spermatogonial 
stem cells by GDNF.  
Current state of Infertility: 
Infertility, as defined by the American College of Obstetricians and 
Gynecologists, the American Society for Reproductive Medicine (ASRM) and the 
World Health Organization (WHO), pertains to the inability of a couple to 
conceive after 12 months of actively trying [4, 5]. Currently, 15% of all couples 
will face challenges in conceiving, where infertility can be attributed to 
abnormalities in both, men and women [6]. However, when we take a closer look, 
we find that ~30-40% of these cases can be solely attributed to the male partner, 
giving good reason to investigate the causes of male infertility in an effort to 
alleviate some of the reproductive challenges these individuals face [7]. Apart 
from the financial and physical stress these couples or individuals deal with, 
infertility has been shown to directly correlate with a lower quality of life in these 
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individuals [8, 9].  Male infertility is initially determined based on sperm count, 
where normal men will have ~ 96 million sperm in their ejaculate; whereas 
infertile men will present with < 5 million sperm [10, 11]. Once diagnosed, treating 
these individuals with the aid of assisted reproductive technology (ART) is often 
challenging, and predicting outcomes of the treatment can be difficult [12-14]. To 
add to this, the possibility of successful outcomes is slimmer in individuals 
diagnosed with azoospermia, where patients lack sperm in their ejaculate. While 
sperm can be surgically retrieved from the testes of some of these men and used 
to fertilize an egg by ICSI [15], additional work in this field of clinical research still 
needs to be done to elucidate effective treatments which would enable more 
infertile men to conceive a child [16]. 
Pathology of interest: Azoospermia: 
 The most severe pathology of infertility is azoospermia, defined as the 
absence of sperm in the ejaculate, affecting ~ 1% of individuals and 10-15% of 
infertile population [17, 18]. Using diagnostic tools and genetic testing, clinicians 
can remarkably achieve upwards of a 90% accurate diagnostic rate in 
distinguishing between the two types of azoospermia; obstructive azoospermia 
(OA) and non-obstructive azoospermia (NOA) [19, 20]. Individuals with OA 
present with complete spermatogenesis, but have a blockage occurring in the 
vas deferens and/or epididymis. Surgeons can use reconstructive procedures to 
repair the blockage, potentially restoring reproductive function in individuals with 
obstructive azoospermia to a relatively normal state. In cases where the 
complete restoration of fertility is not feasible, these individuals are still able to 
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biologically conceive because surgical sperm retrieval occurs with relatively high 
efficiency [21, 22]. However, due to a primary defect in the testes of NOA 
patients, these inidividuals lack the ability to produce adequate numbers of 
sperm, making sperm retrieval (SR) more challenging [23]. In individuals 
diagnosed with the most severe form of NOA, the histologically-defined Sertoli 
cell only (SCO) phenotype, sperm retrieval is at best 20% successful [24]. Thus, 
these NOA individuals who wish to conceive often have to defer to multiple SR 
and ART procedures in order to have their own biological children. While most 
seminiferous tubules in these patients are without any germ cells, biopsies from 
these individuals do reveal foci of spermatogenesis and sperm in 30-60% of NOA 
men [18, 25-27]. Thus, even though NOA men have significantly reduced number 
of SSCs, therapies geared towards increasing the numbers of the remaining 
stem cells might increase the numbers of sperm in their testes, thereby 
increasing the possibility that they might conceive a child either naturally or with 
the aid of assisted reproductive technologies.  
The etiology of NOA can be genetic (ex: Y chromosome microdeletions 
(YCMDs), congenital (ex: cryptorchidism), acquired (radiation, chemotherapy or 
trauma) or idiopathic (80% of the cases) [20, 28]. As previously mentioned, the 
etiology of NOA does not predict SR rates in NOA patients and as a 
consequence, clinicians cannot predict whether sperm retrieval will be 
successful. However, it is interesting to note an increase in the incidence of 
acquired cases. One such example can be attributed to the advancements in 
cancer therapies. While treatments consisting of exposure to radiation or high- 
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dose chemotherapy have contributed to a rise in individuals in remission, such 
treatments can be detrimental to an individual’s fertility [29-31]. For instance, 
exposure to chemotherapy has been linked to infertility stemming from a 
significant decrease in spermatogenic cells, including spermatogonial stem cells 
[29, 32-35]. Treatment has also been shown to induce DNA damage in sperm. 
Results from studies in rodents have shown a higher rate of DNA damage or 
chromosomal aneuploidy in germ cells of exposed animals [36-40]. With that 
said, it is important to keep in mind that the degree of severity in infertility is 
collectively dependent on factors such as age, dose of chemotherapy, and 
frequency of exposure [31, 41]. It is possible for individuals to experience a 
restoration in normal spermatogenesis, either immediately or after non-specific 
delays, which can last up to 4 years or more [42].  
 When it comes to preservation of fertility, cryopreservation of sperm prior 
to chemotherapy exposure is an option. However, only a minimal percentage of 
men pursue this option [43]. In addition, this is not a viable option for pre-pubertal 
individuals, who lack sperm. With the limited option of being treated with 
chemotherapeutic agents that are less toxic to their reproductive organs, these 
pre-pubertal individuals are faced with the dire reality that they could be infertile 
post-treatment [42]. As previously mentioned, in some cases, fertility can be 
restored many years later. However, there are also individuals who present with 
normal sperm counts post treatment, but experience a sequential loss of cells 
over time [42]. Thus, there is a growing need to provide an effective treatment 
plan for such individuals who later on in life express a strong desire to biologically 
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conceive. Research geared towards addressing restoration of fertility or 
preservation of SSCs in these individuals has been primarily based on studies 
performed in rodents. For instance, research in rodents exposed to 
chemotherapy has provided promising results showing that suppression of 
gonadotropins and testosterone, using gonadotropin- releasing hormone 
antagonists and anti-androgens, contributes to a recovery of surviving 
endogenous SSCs [30, 44-47] However, the results have yet to be recapitulated 
in clinical trials [48].  
Diagnosing Non-Obstructive Azoospermia (NOA): 
Non-obstructive azoospermia can be differentiated from obstructive 
azoospermia using family history, genetic testing, hormone analysis and physical 
examination. For instance, hormone analysis is used to identify individuals who 
are NOA due to hypogonadotropic hypogonadism (HH), an endocrine disorder, 
which leads to insufficient gonadotropin stimulation of spermatogenesis [49]. 
These individuals symptomatically present with low levels of follicle-stimulating 
hormone (FSH), luteinizing hormone (LH), and testosterone due to improper 
function of the hypothalamus and/or pituitary gland [18, 49]. In this small subset 
of individuals, exogenous gonadotropins or gonadotropin-releasing hormone 
(GnRH) therapy aids in partial spermatogenic recovery and sperm retrieval [50, 
51]. This recovery is due to increased stimulation of the testis by LH and FSH via 
their receptors on Leydig cells and Sertoli cells, respectively [49, 52]. 
In addition to hormone analysis, genetic testing is often used to identify 
the causes of NOA. One of the most commonly used diagnostic techniques 
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involves identifying individuals with microdeletions in the long arm of the Y 
chromosome referred to as AZF, accounting for ~10% of NOA cases [53]. AZF 
can be classified into four categories (AZFa, AZFb, AZFc, AZFb+c), each 
associated with a varying degree of severity in azoospermia [54, 55]. Majority of 
the cases can be attributed to an AZFc deletion (~80% of cases), followed by 
AZFb deletion (1%–5% of cases), AZFa deletion (0.5%–4% of cases) and 
AZFb+c deletions (1%–3% of cases) [54, 56, 57]. Individuals with the AZFa 
deletion are mostly diagnosed with SCO testicular pathology, implying a poor 
rate of sperm retrieval by biopsy or testicular sperm extraction [53, 58-61]. The 
pathology of individuals presenting with AZFb and AZF b+c deletions is similar to 
SCO individuals, with equally discouraging sperm retrieval (SR) success rates 
[53, 60, 61]. In men who present with complete AZFa, AZFb or AZF b+c 
microdeletions, SR is not recommended. Patients with AZFc deletions show 
signs of sporadic spermatogenesis, with promising SR rates (50%–70%) and a 
high probability of fatherhood by ICSI [53, 56, 62-65]. It is important to note that 
male children born to these individuals inherit the microdeletion and are infertile. 
Even with the current innovations in diagnostic tools, histopathologic examination 
of testicular biopsies are still considered the gold-standard for diagnosing and 
confirming cases and severities of NOA. Visual examination has the unique 
perspective of distinguishing between cases of hypospermatogenesis, germ cell 
maturation arrest, Sertoli-cell-only, or a combination of pathologies [66]. The use 
of biopsies also aids in predicting the chances of successful sperm retrieval [67, 
68]. 
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Treating Non-Obstructive Azoospermia: 
The current standard of care for NOA individuals interested in conceiving 
involves testicular sperm extraction: TESE and microdissection TESE (micro-
TESE) [18, 26].  The main objective of these surgical procedures is to obtain a 
sufficient quantity of good quality sperm to be used with assisted reproductive 
technologies or for cryopreservation, while minimizing testicular damage and 
preserving vasculature. Typically, each seminiferous tubule of an NOA patient 
will only have 0–3 mature spermatids [69, 70].  In conventional TESE, randomly 
selected sections of seminiferous tubules are extracted and those biopsies are 
examined for active areas of spermatogenesis and sperm, which can be found in 
30-60% of NOA men [18, 25-27]. However, this procedure requires the invasive 
acquisition of large testicular biopsies and can compromise androgen function in 
these individuals [71, 72]. Micro-TESE, developed by Dr. Peter Schlegel, 
provides a better alternative to TESE because active areas of spermatogenesis 
are identified with the aid of an operating microscope (Figure 1) [73]. This 
procedure begins with an incision in an avascular area of the testis, as in 
conventional TESE, and enlarged seminiferous tubules characteristic of active 
spermatogenesis are identified under ×15–25 magnification. As a result, 50-70 
fold smaller biopsies are extracted and the chances of vascular injury or other 
complications are significantly decreased. In addition, this procedure leads to SR 
in one-third of the cases previously thought not possible [71, 73-75]. Patients 
needing additional surgeries are advised to wait at least 6 months between 
procedures to allow for adequate recovery. In turn, this recovery period 
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significantly improves the chances of sperm retrieval (25% vs. 80%) in a 
subsequent operation [71, 73]. When possible, cryopreservation of remaining 
testicular sperm is recommended, especially after successful sperm retrieval in 
NOA patients. However, the most successful strategy for conception in NOA 
individuals involves the use of fresh testicular sperm. It should be noted that 
successful sperm retrieval coupled with ART does not ensure successful live 
births. For instance, studies performed by Esteves and colleagues have reported 
significantly lower pregnancy rates and live births using sperm retrieved from 
NOA individuals [76-79]. In instances where live births were successful, the 
authors stated that additional follow up studies were required to elucidate the 
physical, neurological, and developmental outcomes of children conceived from 
sperm acquired from NOA individuals [80, 81]. 
 As previously mentioned, recent findings are reporting focal areas of 
active spermatogenesis in NOA men. These focal areas must contain 
spermatogonial stem cells, which under the appropriate stimulus might expand in 
number and fill empty stem cell niches. This area of research is of particular 
interest to us because of the potential it holds towards creating fertility options for 
infertile patients who have a strong desire to have biological children.  
A brief introduction to spermatogenesis:  
The development of new therapies for infertile men requires a 
fundamental understanding of the process by which sperm are formed, 
spermatogenesis. This process takes place in the testis, which is sectioned into 
two compartments. The majority of the testis is comprised of seminiferous 
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tubules, the site of spermatogenesis. The remaining ~10% of the testis is 
comprised of the interstitium, made up of Leydig cells, blood vessels, immune 
cells and vasculature [82, 83]. Spermatogenesis can be divided into 3 stages: 
mitotic proliferation of spermatogonia, meiosis, and spermiogenesis [84]. During 
the first phase of this process, some of the replicating spermatogonial stem cells 
begin to differentiate, thereby forming transit amplifying progenitor 
spermatogonia [85, 86]. These progenitors amplify through mitotic division. Stem 
cells differ from and progenitor cells in that they have the potential to replicate 
indefinitely, while progenitors proliferate a limited number of times [87]. 
Progenitor spermatogonia ultimately generate fully differentiated spermatogonia. 
In the mouse after 5 additional mitotic divisions, preleptotene spermatocytes are 
formed, and meiosis commences [87]. The finals steps of spermatogenesis begin 
with spermiogenesis, which refers to a cytological transformation in round 
spermatids, forming spermatozoa. These cells are then released into the lumen 
of the seminiferous tubule by a process called spermiation [84]. 
Spermatogenesis requires this sequential transition from one step to another. 
Disruption during any of these transitions or stages can lead to infertility. 
Spermatogenesis in rodents and humans: 
In mammals, spermatogonial differentiation and germ cell development is 
a highly synchronized process, with spermatogonia, spermatocytes and 
spermatids at specific states of development always found together in what are 
the stages of the cycle of the seminiferous epithelium. There are 12 distinct 
stages in mice and 14 in rats. In almost all mammals, except great apes and 
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humans, one stage can be identified per cross-section of a seminiferous tubule 
and sequential movement through all the stages constitutes a complete cycle 
[88, 89].  One cycle lasts 8.62 and 13 days and spermatogenesis takes 34.5 and 
51.6 days in mice and rats, respectively [90]. The organization of stages is 
different in humans. Clermont described six stages in the human, and 2-4 
different stages can be found in the same seminiferous tubule cross-section, 
adding significantly to the challenge of identifying distinct germ cells and/or 
stages present in each cross-section [91]. In humans, spermatogenesis takes 64 
days to complete, where one cycle takes 16 days [90]. Thus, when comparing 
histology of the seminiferous tubule in rodents and humans, we can conclude 
that rodents display a linear pattern with one stage present per cross section in 
rodents, while humans display a patchy pattern where a cross section contains 
germ cells present in multiple stages.  
Morphological and molecular characteristics of undifferentiated spermatogonia in 
rodents and humans: 
Collectively, spermatogonial stem cells and progenitor spermatogonia 
comprise a population of cells that are often called undifferentiated 
spermatogonia.  Oakberg was the first to define these cells by their morphology, 
and classified them as Asingle (As), Apaired (Apr) or Aaligned  (Aal) spermatogonia. As 
spermatogonia can be identified because they exist as single cells and lack 
intercellular bridges, which can be found between Apr or Aal spermatogonia [92]. 
Two cells connected by an intracellular bridge are called Apr spermatogonia. 
Longer chains of connected undifferentiated spermatogonia are Aal 
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spermatogonia. All of these undifferentiated spermatogonia can be found in 
areas adjacent to the stem cell niche, are proposed to be associated with niche 
vasculature [93-95] and are present at all stages of the of the seminiferous 
epithelium. In the rodent testis, there are around 35,000 As spermatogonia, 
contributing to ~11% of the undifferentiated spermatogonial population and 
0.03% of the germ cell population [90, 96]. In the mouse, spermatogonial stem 
cells (SSCs) represent a subpopulation of As spermatogonia that can 
asymmetrically divide to self-renew or give rise to Apr spermatogonia, depending 
on the appropriate environmental cues. It is estimated that each mouse testis 
contains 3,000 to 6,000 functional SSCs [95]. Once formed, Apr spermatogonia 
undergo clonal expansion to generate chains of Aal spermatogonia, which 
typically consist of 4, 8 or 16 cells. In the mouse, Aal spermatogonia differentiate 
to form A1 spermatogonia, which sequentially undergo mitotic divisions to give 
rise to A2, A3 , A4, Intermediate (In) and Type B spermatogonia. Thus, through 
this clonal expansion, each SSC division has the capacity to expand as much as 
4000-fold, giving rise to as many as 4096 spermatids [97]. Detailed long-term 
lineage tracing and transplantation studies have revealed two molecular markers 
whose expressions are restricted to As spermatogonia in the adult mouse testis, 
PAX7 and ID4 [98-101], and thus are currently the optimal markers for SSCs. 
These cells also express GFRα1, THY1, POU5F1, PLZF, NGN3, GRP125 and 
α6- Integrin, as do progenitor spermatogonia [91]. The transition from 
undifferentiated to differentiated spermatogonia is often marked by cKIT 
expression in Type A and B spermatogonia [102].  
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In humans, spermatogenesis begins with two distinct types of 
spermatogonia, Adark (Ad) and Apale (Ap) [82, 97, 103, 104]. Ad spermatogonia are 
referred to as the reserve stem cell population, which normally remain 
unproliferative unless significant numbers of spermatogenic cells are lost 
because of irradiation, chemotherapy or other injuries [97, 103, 105, 106]. 
Whereas, Ap spermatogonia proliferate regularly to self renew or undergo one 
division to form a type B spermatogonia. Ad and Ap spermatogonia are 
morphologically distinct; the nuclei of Ad spermatogonia contain a large vacuole-
like cavity called a chromatin rarefaction zone [107]. In contrast, Ap nuclei do not 
have this zone and contain 1-3 nucleoli attached to the nuclear membrane. While 
there is no clear molecular definition of SSCs in human, von Kopylow and 
colleagues have shown evidence that FGFR3 is a reliable marker for Ad 
spermatogonia by demonstrating that FGFR3+ cells expressed the chromatin 
rarefaction zone [108]. Recently, our lab and other researchers have also 
observed a hybrid phenotype of dark and pale spermatogonia, where these cells 
share a few characteristics of both cell types [103]. While a true population of 
SSCs in humans remains to be identified, there is some evidence suggesting that 
a subset of Ap spermatogonia may also contribute to the SSC population. For 
instance, Schulze and colleagues have shown the presence of mostly Ap 
spermatogonia, among very rare Ad cells, in recipients of radiation therapy and in 
post pubertal individuals with crytorchid testes [106]. Compared to rodents, each 
SSC division in humans only gives rise to 32 spermatids [97]. Like rodents, 
human undifferentiated spermatogonia express a broad range of molecular 
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markers comprising of UTF1, MAGE-A4, FGFR3, GFRα1, α6-INTERGRIN, 
PLZF, SALL4, UTF1, UCHL1 and THY1 [104, 105, 108, 109].   
Sertoli cells and their role in spermatogenesis: 
Spermatogenesis and male fertility relies on Sertoli cells to produce and 
respond to a complex spectrum of paracrine and endocrine factors influencing 
spermatogonia [110, 111]. SSC and/or progenitor maintenance and behavior is 
heavily influenced by the stem cell niche, created at least in part by the Sertoli 
cell [86]. Located at the basement membrane, these somatic multitaskers provide 
immunological, nutritional, and structural support as well as growth factors and 
cytokines that target different cells in the spermatogenic lineage. By forming tight 
junctions between neighboring Sertoli cells, they also create the blood-testis-
barrier, which separates meiotic and haploid germ cells in the adluminal 
compartment from SSCs, progenitor spermatogonia and mature spermatogonia 
in the basal compartments of the seminiferous tubule [86, 112]. This barrier 
prevents molecules greater than 1000 daltons from moving into and out of the 
seminiferous tubule, protecting the germ cells from inflammatory interactions with 
leukocytes and antibodies [113-116]. Sertoli cells also have phagocytic activity 
and can degrade apoptotic cells or residual bodies, clearing the testicular 
environment of unwanted debris [117]. It is equally important to have adequate 
quantities of Sertoli cells, ensuring normal spermatogenesis by establishing 
proper testicular size, and germ cell and sperm yields [118]. Sertoli cells 
proliferate and mature during finite periods of development to form a stable 
population; where their maturation is marked by morphological changes in the 
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nucleolus, shedding of their proliferative activity, down regulation of anti-Mullerian 
hormone and aromatase, and up-regulation of GATA-1 expression [119]. Once 
mature and stable, Sertoli cells express Wilm’s tumor protein (WT1) and GATA-4 
binding protein [120-123]. In addition, Sertoli cells express the transmembrane 
growth factor, Kit ligand (KITl), which binds to the receptor ckit, to regulate the 
proliferation and/or differentiation of Type A spermatogonia [124-127].  Thus, due 
to their critical role, it is reasonable to assume that any abnormality in Sertoli cell 
number, maturation, and/or function can lead to a disruption in spermatogenesis 
and in some cases infertility.   
The role of glial cell-line derived neurotrophic factor (GDNF) in spermatogenesis: 
Sertoli cells aid in regulating SSC self-renewal or differentiation by 
secreting a variety of hormones, growth factors and cytokines into the SSC 
environment. Furthermore, they mediate the effects of follicle stimulating 
hormone (FSH) and testosterone on spermatogenesis, because of their 
expression of receptors for those hormones. [113]. Sertoli cells also secrete 
growth factors such as FGF2 and EGF, which have been shown to be necessary 
for in vitro SSC proliferation [128]. However, FGF2 and EGF are not solely 
enough to stimulate in vivo self-renewal of SSCs [128]. To date, GDNF, secreted 
by Sertoli cells, is the only paracrine factor in the testis shown to be absolutely 
required in vivo by SSCs [1, 129].  
GDNF has been shown to be essential for neuronal, renal and testicular 
development [130]. For instance, GDNF knockout mice are embryonic lethal and 
die within the first day of birth due to severe abnormalities in renal and neuronal 
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development, such as absent ureteric buds, kidneys and enteric neurons [131-
133]. Mechanistically, GDNF acts via a complex consisting of a 
glycosylphosphatidylinositol (GPI)-anchored cell surface ligand binding subunit 
(GFRα1) and a tyrosine kinase transmembrane protein (RET) [134, 135]. In the 
testis, the downstream effects of GDNF signaling lead to the phosphorylation and 
subsequent activation of multiple signaling pathways, such as the AKT and SRC, 
causing an increase in SSC proliferation [136-139]. Mice lacking the Ret or 
GFRα1 receptor subunits  show the same phenotype of severe abnormalities in 
renal and neuronal development [140-143]. While Gdnf +/− mice do survive and 
are fertile, histological analysis of their seminiferous tubules reveal that 
spermatogenesis does not occur normally [1]. For instance, the histology of 
young Gdnf +/− mice reveal spermatids in ectopic positions or phagocytosed by 
Sertoli cells. In older Gdnf +/− mice, germ cells were absent in majority of the 
seminiferous tubules, resulting in a Sertoli cell only phenotype. In contrast, GDNF 
over expression under the testis-specific human translation elongation factor–1a 
(EF-1a) promoter in transgenic mice resulted in an accumulation of stem and 
undifferentiated spermatogonia [1, 144]. However, it is important to note that as 
these cells accumulated, they formed testicular tumors and led to a state of 
infertility because they failed to give rise to differentiated spermatogonia and 
eventually sperm [145]. Together, these elegant in vitro and in vivo findings 
provide strong evidence that altering GDNF signaling to SSCs throughout the life 
of the animal has a significant effect on their numbers. 
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Post-transcriptional and post-translation regulation involving GDNF: 
MicroRNA’s (miRNA’s) have been widely studied and shown to be 
involved in regulating the stem cell niche at the post-transcriptional level. For 
instance, over-expression of miRNA-221 and miRNA-222 in the mouse has been 
shown to inhibit the effects of retinoic acid, halting the transformation of 
undifferentiated spermatogonia into differentiated spermatogonia, which are c-kit 
positive [146].  GDNF can actually enhance the expression of these miRNA’s, 
while retinoic acid dampens the effect [146]. Similarly, miRNA-146 has been 
implicated in affecting the expression of differentiation factors such as c-kit, Stra8 
and Sohlh2 [147]. MicroRNA’s have also been shown to influence mouse SSC 
self-renewal. He and colleagues have shown that miRNA-20 and miRNA-106a 
influence self-renewal of spermatogonial stem cells by targeting Stat3 and Cyclin 
D1 [148]. On the other hand, there is limited information regarding the impact of 
post-translational modifications of GDNF on its biological activity and clinical use. 
In mammalian cells, GDNF exists as a preproprotein, which dimerizes during 
secretion and folds by forming a disulfide bond. Following this, it is modified via 
N-linked glycosylation and proteolysis [149]. Piccinini and colleagues have 
shown that GDNF is modified by N-linked glycosylation (Asn49), which assists in 
the proteolytic processing of GDNF and makes it more stable, which may aid in 
its clinical use [149]. In regards to its therapeutic administration, it is recommend 
that GDNF, like other therapeutic proteins, be administered in a form inclusive of 
the protein structure and glycosylation pattern comparable to its native form 
[150]. When administered in this manner, studies in the pig have shown that pure 
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SUMMARY   
As previously mentioned, majority of our knowledge regarding the 
regulation of spermatogonial stem cells is based on studies in the mouse. 
Previous studies have shown that spermatogonial stem cells sustain 
spermatogenesis through a continual maintenance of the stem cell pool, either 
through self-renewal or differentiation [152]. In 2000, Meng and colleagues 
showed that glial cell line-derived neurotrophic factor (GDNF) was involved in 
SSC regulation, by influencing SSC self-renewal [1]. They specifically showed 
that transgenic mice overexpressing GDNF demonstrated an accumulation in 
undifferentiated spermatogonia and a termination in differentiating 
spermatogonia in their seminiferous tubules. On the other hand, GDNF 
heterozygous mice showed a progressive loss in spermatogonia [1]. In both 
scenarios, these mice were rendered infertile. Similarly, animals with deficiencies 
in Ret or GFRα1 exhibit similar phenotypes [2, 153, 154]. These data form the 
foundation of our current understanding in the field: GDNF influences SSC 
behavior, in vitro and in vivo. Specifically, we know that under high 
concentrations of GDNF, SSCs undergo self-renewal. In contrast, under low 
concentrations of GDNF, SSCs preferentially differentiate.  
Despite the progress in our understanding of how SSCs are directly 
influenced by GDNF, there are still significant gaps in our knowledge. For 
instance, little is known about how SSCs are regulated in vivo in normal adult 
mice and humans. These gaps in knowledge primarily stem from the limitations 
we face in terms of the experimental methods available to specifically manipulate 
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SSC numbers or signaling to these cells in adult mice and men. We have been 
able to overcome these limitations in the mouse by using a unique chemical-
genetic approach, allowing us to reversibly inhibit the downstream signaling 
effects of GDNF. Using this approach, we were able to prove that GDNF acutely 
regulates the numbers of spermatogonia stem cells in the normal adult mouse 
testis. Based on similarities in spermatogenesis between mice and men, we 
wanted to test the hypothesis that levels of this growth factor in fertile human 
testes are similar to those in rats and mice, thereby supporting the hypothesis 
that GDNF is essential for the in vivo maintenance of human SSCs and 
progenitor spermatogonia. If true, then our hypothesis would predict that the 
testes of men with NOA (SCO) testes would express low levels of GDNF. Thus, it 
would follow that restoring GDNF levels in these men would aid in the partial 
recovery of spermatogenesis, by providing the appropriate stimulus needed for 
SSCs to self-renew and replenish the stem cell pool. As previously mentioned, 
with the exception of invasive surgeries with low success rates, there is no 
effective treatment for NOA patients. However, with the discovery of focal areas 
of spermatogenesis, access to SSCs can have direct implications in treating a 
subset of infertile individuals, opening up a new field of research and potential 
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FIGURE LEGEND 
 
Figure 1. Schematic showing the steps involved in microdissection- TESE. Figure 
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CHAPTER 2: Understanding the role of GDNF in regulating stem and progenitor 
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ABSTRACT 
Male fertility is based on the delicate balance between re-newel of stem 
cells and their proliferation and differentiation. The growth factor glial cell line-
derived neurotrophic factor (GDNF) has been shown to be critical in establishing 
this pool in the prepubertal animal, but its in vivo function in the normal adult 
testis has never been directly studied. Thus, the mechanisms regulating the size 
of this stem cell pool in the adult still remain unknown. Using a unique in vivo 
chemical-genetic approach, we were able to address this gap in our knowledge 
by investigating the effects of inhibition of the GDNF signaling complex in the 
normal adult testicular environment. The genetic aspect of this approach refers to 
the introduction of a single amino acid mutation (V805A) into the ATP binding site 
of Ret, the kinase subunit of the GDNF receptor. While this mutation does not 
affect normal GDNF signaling, it renders the receptor susceptible to inhibition by 
a bulky ATP competitive inhibitor, NA-PP1. Using this strategy, we were able to 
show that after the downstream effects of GDNF signaling was blocked in adult 
mice for 11 days, most spermatogonial stem cells were lost. The rare surviving 
cells expressed the stem spermatogonial markers, GFRα1 and Zbtb16. In 
addition, testicular spermatogonial stem cells (SSCs) message levels were 
reduced, with the most substantial reduction reported in Ret mRNA levels. Taken 
together, these decreases reflect the loss of spermatogonial stem cells and/or 
progenitor spermatogonia. Interestingly, when signaling was restored by 
cessation of NA-PP1 treatment, the remaining stem cells initiated the restoration 
of spermatogenesis. However, when the signaling complex was inhibited for a 
	   45	  
prolonged period of 30 days, the process of spermatogenesis was permanently 
disrupted, indicating that the SSCs had been lost. These results are the first of its 
kind to provide direct evidence that GDNF regulates the numbers of 
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INTRODUCTION 
Spermatogonial stem cells are the foundational cells of spermatogenesis, 
and their preservation is essential for male fertility [1]. The mechanisms that 
control their preservation prevent the pathological accumulation of stem cells or, 
alternatively, the depletion of the stem cell pool. Sertoli cells have been shown to 
be an integral part of this regulation because they secrete GDNF, which has 
been shown to promote self- renewal over differentiation of replicating stem cells 
[1]. However, this has yet to be shown in vivo, in the context of a normal adult 
testicular environment.  
GDNF has been demonstrated to be critical in regulating the numbers of 
SSCs in in vitro and in vivo studies. For instance, long-term culture studies with 
GDNF have shown that it is required to maintain and expand SSCs, as measured 
by their ability to restore spermatogenesis when transplanted into a germ cell-
deficient testis [2]. This suggests that GDNF preferentially promotes self-
renewing replication of SSCs. If true, then inhibition of GDNF signaling would 
result in a rapid loss of some of these cells within one cell cycle, which is 
estimated to be 43-46 hours in duration [3-8]. Contradictorily, cultures enriched in 
mouse SSCs deprived of GDNF for 3 or 6 days result in a significant increase in 
the numbers of functional stem cells, as evaluated by transplantation, a result 
identical to what was observed when the cells were incubated with GDNF [9]. 
The numbers of spermatogonia that were non-functional stem cells substantially 
increased when GDNF was added to the cultures, suggesting that GDNF may 
not always preferentially promote self-renewal over differentiation. This 
	   47	  
hypothesis was also challenged by evidence in rat stem spermatogonial cultures, 
where one stem cell would undergo self-renewing replication, while another in 
the same microenvironment would produce differentiating progeny [10]. Taken 
together, these results suggest that cell fate decisions may be regulated by 
mechanisms intrinsic to the stem cells themselves.  
In vivo studies using transgenic overexpression or a gene knockout model 
of GDNF have tremendously contributed to our understanding of how GDNF 
regulates SSCs and progenitor spermatogonia by examining the consequences 
of altered GDNF expression from the time of birth or earlier. From these studies, 
we know that GDNF over expression results in the formation of clusters of 
undifferentiated spermatogonia, where many of the cells in these clusters are 
eliminated via apoptosis, resulting in infertile mice with seminiferous tubules 
primarily lined only with a rim of spermatogonia or Sertoli cells [11]. However, the 
authors were unable to determine if these stem cells were functional because 
they expressed the transgene, and consequently, repeated their abnormal 
phenotype when transplanted into a germ cell-deficient testis [12, 13]. Similarly, 
testes of GDNF null mice are devoid of most germ cells within 7 days, and the 
few remaining germ cells did not replicate [13]. Mice haploinsufficient for GDNF 
also show a progressive loss of spermatogonia, spermatocytes and spermatids, 
resulting in a lack of germ cells in mature mice. While this may support the 
hypothesis that GDNF promotes self-renewal of stem spermatogonia, it should 
be noted that the first wave of spermatogenesis is initiated from gonocytes, and 
not stem spermatogonia [14]. This suggests that a complete deficiency in GDNF 
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at birth would result in the failure of the gonocytes to give rise to a stem 
spermatogonial pool of normal size and function. Taken together, previous in vivo 
studies have demonstrated that GDNF is essential for establishing the stem 
spermatogonial pool in the immature testis. However, direct analysis of the 
effects of the loss of GDNF signaling and the consequences of restoration of this 
signaling in the normal adult mouse testis have yet to be elucidated. 
Based on the critical relationship between a functional stem cell pool and 
male fertility, we concluded that a new paradigm was necessary to allow one to 
study the downstream effects of GDNF signaling on spermatogonial stem cells 
within the physiological context of the normal adult testis. Therefore, we 
employed the use of a highly specific chemical-genetic approach, which allowed 
for the reversible inhibition of GDNF signaling [15-18]. This signaling normally 
occurs by first binding to the receptor, GFRα1. This dimeric complex then binds 
to the tyrosine kinase subunit of the receptor, Ret, which leads to activation of 
signaling by phosphorylation and autophosphorylation, and completes the 
signaling complex (Figure 1A) [19]. Our mice carry a single amino acid mutation 
(V805A) in Ret, which has no effect on baseline Ret kinase activity, but 
substantially increases its affinity for the ATP competitive inhibitor, NA-PP1 
(Figure 1B) [20]. While Ret is also a subunit for receptors of other GDNF family 
members, knockouts of the ligand binding subunits for these other receptors 
have no direct effect on testis morphology or male fertility [21-23]. This unique 
chemical-genetic approach has allowed us to investigate the impact of the 
inhibition and restoration of the GDNF signaling complex on SSCs and progenitor 
	   49	  
spermatogonia in the normal adult mouse testis. Using this approach, we tested 
the hypothesis that GDNF is essential for maintaining the spermatogonial stem 
cell pool in the normal adult testis. Our results show that the inhibition of GDNF 
signaling for acute, intermediate, and prolonged periods of time leads to the 
progressive loss of stem and progenitor spermatogonia. The data also show that 
restoration of GDNF signaling results in an amplification of the remaining stem 
cells, which fill empty stem cell niches in an effort to restore the stem cell pool 
and eventually, normalize spermatogenesis [24].  
MATERIALS AND METHODS 
Animals: 
Mice carrying a mutation (V805A) in the ATP binding site of Ret were 
generated as previously described by Dr. Joseph Savitt, Department of 
Neurology, Johns Hopkins School of Medicine [25]. The frt-flanked neomycin 
resistance cassette in the targeting construct (Figure 2) was removed by crossing 
these mice with B6; SJL- Tg(ACTFLPe) 9205 DG M/J mice (Jackson 
Laboratories, Bar Harbor, ME). Homozygous Ret (V805A) mice were identified 
by PCR analysis of genomic DNA using primers that crossed the 5’ LoxP site of 
the targeting construct:  
Ret F (36580): CCTTGGGCCTGCTGAGCACGGG  
RET R (36858): GGAGGCAGGAAGGCCTGTGC  
PCR conditions were: 4 minutes at 95°C followed by 35 cycles of: 30 sec at 
95°C, 45 sec for 57°C, 45 sec at 72°C, followed by a 7 min incubation at 72°C. 
Mice were 70-100 days of age at the start of the experiment and the Johns 
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Hopkins University Institutional Animal Care and Use Committee approved their 
use.  
Testing the efficacy of the different ATP competitive inhibitors of Ret (V805A):  
The abilities of different bulky ATP competitive inhibitors to block Ret 
(V805A) kinase activity were tested by Dr. Savitt. Full-length cDNAs for wild type 
Ret and Ret (V805A) were cloned into the pRK5 vector (BD Biosciences; San 
Diego, CA) and transfected into confluent HEK 293 cells using lipofectamine 
(Invitrogen, Carlsbad, CA). After three hours, medium with serum was added 
along with NA-PP1 or a related inhibitor. Cells were lysed 16 hours later, 
fractioned by SDS- PAGE, blotted onto nylon and incubated with Anti-phospho 
Ret (Y1062) (Santa Cruz Biotechnology, Santa Cruz, CA) and the ECL detection 
system (GE Healthcare, Piscataway, NJ). Some blots were re-probed for total 
Ret (Santa Cruz Biotechnology).  
Synthesis and administration of NA-PP1:  
NA-PP1 and related compounds were synthesized by the laboratory of 
Kevan Shokat (UCSF) as previously described [20]. To convert NA-PP1 into an 
HCl salt, 400 mg of NA-PP1 was dissolved in 40 ml of methanol plus 5 ml of 
1.25M HCl in methanol. NA-PP1 was dissolved by heating and stirring, the salt 
was dried using a rotovap, dissolved in ethanol (62.5 mg/ml) and stored under 
nitrogen at -20°C. One part of NA-PP1 in ethanol was diluted into 9 parts in 
saline:cremophor EL (7:2) and 62.5 mg NA-PP1/kg body weight was injected 
subdermally between the scapulae. Vehicle-treated control mice were injected 
with 100 microliters of ethanol:saline:cremophor EL (7:2:1) per 100 grams body 
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weight. Additional studies showed that GDNF inhibition studies, a dose response 
study revealed that the minimal dose of NA-PP1 required for inhibition of GDNF 
signaling was 43.7 mg/Kg (Figure 3).  
Tissue Collection:  
 Whole testes and seminiferous tubules were collected from mature male 
mice (Bl6SJL/J genetic background). Collection of tissues was approved by the 
Institutional Animal Care and Use Committee of Johns Hopkins University.  
Tissue Preparation and Fixation for Immunohistochemistry:  
Adult mouse testes were stripped of the tunica, releasing compacted 
seminiferous tubules. These tubules were manually separated in PBS, fixed for 2 
hours in 4% paraformaldehyde at room temperature and washed in PBS (four 
times, 30minutes/wash).  
GFRα1 Immunohistochemistry in whole–mounts of seminiferous tubules of mice:  
4% PFA fixed tubules were blocked with PBS and 1% BSA (PBS-B) for 1 
hr at RT in netwells in a 12-well plate. The tubules were washed with PBS once 
for 5 minutes and incubated overnight with primary antibody (1: 100, Goat anti-rat 
GFRα1, R&D systems, catalog # AF560) PBSB (1% BSA per 100ml PBS) at 
4°C. The next day, the tubules were washed 6X, 15 minutes/wash in PBSBT 
(0.1% Trition X-100 in 1% BSA per 100ml PBS) and incubated overnight at 4°C 
with secondary antibody (200ul/well, 1:500 anti goat- Alexa 488) in PBSBT. Once 
the tubules came into contact with secondary antibody, the plate was wrapped in 
aluminum foil to prevent photobleaching of the fluorochrome.  On the last day, 
the tubules were washed 6X for 15 minutes each with PBSBT and mounted as 
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described below. 
Zbtb16 (PLZF) Immunohistochemistry in whole –mounts of seminiferous tubules 
of mice:  
 Gradual dehydration was performed on 4% PFA fixed tubules, followed by 
sequential washing for 10 minutes each in 25%, 50%, 75%, and 95% MeOH in 
PBS and twice in 100% MeOH. The tubules were then incubated in 3ml/net well 
of MEOH: DMSO: H2O2 (4:1:1) at RT for 2 hours and rehydrated for 10 
minutesminutes each in 3ml of 50% and 25% MeOH in PBS and twice in 3ml 
PBS for 15 minutes. Tubules were blocked in cold PBSMT (0.5% Trition X-100 in 
2% nonfat dried milk powder per 100ml PBS) for 2 hours and incubated overnight 
in primary antibody (4 µg/ml AntiPLZF: goat anti-PLZF, R&D Research systems, 
AF2944) diluted in PBSMT at 4°C. The plate was placed in a tupperware 
container with water saturated paper towels to prevent the primary antibody from 
drying out. The following day, tubules were washed with cold PBSMT (2X 
15minutes, 5X 1hr) and then transferred to a 24 well plate for an overnight 
incubation at 4°C with secondary antibody (4 µg/ml Alexa fluor-488 rabbit anti-
goat IgG, Invitrogen, Carlsbad, CA) diluted in PBSMT. Once the tubules came 
into contact with secondary antibody, the plate was wrapped in aluminum foil. 
The following day, the tubules were washed in cold PBSMT (2x for 15 minutes 
and 4X for 1 hr) and PBS (2X for 10 minutes). Following washing, tubules were 
mounted as described below. 
 
	   53	  
Cleaved casapse 3 Immunohistochemistry in whole –mounts of seminiferous 
tubules of mice:  
4% PFA fixed tubules were blocked with 1% BSA in 1X PBS for 1 hour at 
RT and rinsed twice with PBS for 15 minutes. The tubules were then incubated 
with cleaved caspase 3 (1:500 Rabbit antibody, Cell Signaling Technologies, 
catalog # 96615) in 1% BSA per 100ml PBS overnight at 4°C on the shaker. The 
next day, the tubules were washed 6X, 15 minutes/wash in PBSBT (0.1% Trition 
X-100 in 1% BSA per 100ml PBS) and incubated in secondary antibody (1:1000 
Donkey Anti-rabbit, Alexa fluor-555 donkey anti-rabbit IgG (H+L), Invitrogen, 
Carlsbad, CA, catalog # A31572) in PBSBT overnight at 4°C on a shaker. The 
next day, the tubules were washed 6X, 15 minutes/wash in PBSBT, followed by 
sequential washing for 10 minutes each in 25%, 50%, 75%, and 95% MeOH in 
PBS. The tubules were then rehydrated for 10 minutes each in 3ml of 50% and 
25% MeOH in PBS and twice in 3ml PBS for 15 minutes. The tubules were then 
blocked with 1% BSA in 1X PBS for 1 hour at room temperature on a shaker and 
rinsed twice with 1X PBS for 15 minutes/each, and incubated overnight in 
primary antibody (1:1000 AntiPLZF: goat anti-PLZF, R&D Research systems, 
AF2944) diluted in PBSMT at 4°C. The next day, the tubules were washed 6X, 
15 minutes/wash in PBSBT and incubated with secondary antibody (1:200 Alexa 
fluor-488 donkey anti-goat IgG, Invitrogen, Carlsbad, CA, catalog # A11055) 
diluted in PBSBT. Once the tubules came into contact with secondary antibody, 
the plate was wrapped in aluminum foil. On the last day, the tubules were 
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washed 6X, 15 minutes/wash in PBSBT, 2X with 1X PBS for 10 minutes/each 
and mounted as described below. 
Mounting Seminiferous tubules: 
The slides are prepared for mounting by placing four drops of clear nail 
polish on the slide to replicate the dimensions of the coverslip. The purpose of 
this is to create raised edges to prevent the cover slip from crushing the tubules. 
A few drops (2-3) of PBS are placed on the slide to which the tubules are added 
and separated using forceps. Any excess PBS was soaked up gently via a 
Kimwipe and a drop of Vectashield was placed to coat the tubules. The coverslip 
was placed and secured by sealing the edges with clear nail polish. The slides 
were allowed to dry for at least 20 minutes before observing.   
Analysis of Zbtb16+, GFRα1+ or cleaved caspase 3+ spermatogonia: 
Digital images of Zbtb16+ and GFRα1+ spermatogonia were captured with 
a Nikon Eclipse Microscope equipped with a cooled CCD camera (QImaging, 
Surrey, BC, CA) and imported into iVision (Biovision Technologies, Exton, PA). 
Zbtb16 or GFRα1 marked cells were quantified based on their classification as 
Asingle (As) spermatogonia, a subpopulation of which are the functional stem cells, 
Apaired (Apr) or as Aaligned (Aal) spermatogonia, which form chains of 4-16 cells 
(Figure 4). A change in the ratio of Apr or Aal spermatogonia to As cells was 
indicative of increased differentiation of replicating stem cells. For cleaved 
caspase 3, whole mounts of seminiferous tubules were optically sectioned (2.3 
µm) using a Zeiss LSM 710 Confocal Microscope and images of ZBTB16+ and / 
or cleaved caspase 3+ spermatogonia were captured and quantified. Same 
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settings were used for imaging negative controls (isotype control IgG).  
Whole testis fixation:  
To evaluate the duration in loss of functional stem cells due to inhibited 
GDNF signaling, testis were collected after treatment and fixed to observe the 
loss and depletion of mature spermatogenic cells. Testes were fixed in 5% 
glutaraldehyde in cacodylate buffer, postfixed in osmium tetroxide, embedded in 
Epon 812, and 1 micron thick sections stained with Toluidine blue. Four to six 
different cross sections per testis were evaluated and a minimum of 300 tubules 
per testis were examined for the presence or absence of spermatogonia, 
spermatocytes and/or spermatids. Tubule cross-sections that were devoid of all 
spermatogonia, spermatocytes and round spermatids were considered to lack 
spermatogonial stem cells. To assess any toxic or off-target effects, kidneys and 
livers were emersion fixed in Bouin’s fixative, embedded in paraffin and 5-micron 
sections stained with hematoxylin and eosin were examined.  
Measurement of transcript levels: 
RNA was isolated using RNAeasy kits (Quigen, Valencia CA), cDNA was 
synthesized using Superscript III (Invitrogen) and transcripts encoding Zbtb16, 
GFRα1, Ret and 18S rRNA were quantified using TaqMan primers (Life 
Technologies Corp, Carlsbad, CA). Standard curves for each assay were 
generated from cloned, sequence-verified cDNA standards and the amount of 
each transcript was normalized to the amount of 18S rRNA in each sample.  
Statistical analysis: 
Cell counts were analyzed using a nested ANOVA and other data were 
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analyzed by ANOVA. Statistical analysis used StatView (SAS Institute Inc, Cary, 
NC). Differences were defined as significant at p≤0.05.  
RESULTS 
 
Characterization of Ret (V805A) mice and their response to NA-PP1: 
To permit for the reversible inhibition of GDNF signaling, the Ret kinase 
domain was engineered to allow for the substitution of an inert small molecule, 
which acted as a high affinity inhibitor of Ret’s kinase activity. This V805A 
mutation was selected by comparing the sequence of RET to other kinases that 
have been similarly targeted (Figure 5). Transient transfection analysis confirmed 
that this mutation did not affect baseline kinase activity; but rather, it made RET 
susceptible to inhibition by NA-PP1  
(Figure 6). Mice homozygous for this mutation were generated and tested for the 
ability of NA-PP1 to inhibit Ret by injecting it into pregnant mice from embryonic 
day 9 until birth. Homozygous pups born to these mothers died by post-natal day 
2 due to hypoplastic kidneys, reiterating the Ret knockout phenotype [26]. 
However, treating adult male Ret (V805A) mice or wild-type mice for 30 days with 
NA-PP1 did not affect body weight or kidney & liver histology (Figure 7 & 8). 
Additionally, there was no difference in testes weights of wild-type and Ret 
(V805A) mice treated with NA-PP1 for 20 days, respectively (Figure 7). Thus, 
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Inhibition of the GDNF signaling complex in the adult leads to the loss in 
expression of cells expressing the stem spermatogonial markers, GFRα1, Zbtb16 
and Ret:  
To test the hypothesis that GDNF is required by spermatogonial stem cells 
in the normal adult testis, adult male Ret (V805A) mice were treated with NA- 
PP1 for 5,11 or 20 days and examined for GFRα1+ and Zbtb16+ spermatogonia. 
Keeping in mind that it takes ~ 35 days for one full cycle of spermatogenesis to 
take place in the mouse, these time-points were chosen because they represent 
acute (5 days), intermediate (11 days), and prolonged (20 days) periods of 
inhibition [27]. In mice where GDNF signaling was inhibited for 5 days, we 
observed a more rapid loss in GFRα1+ spermatogonia when compared to 
Zbtb16+ spermatogonia and control mice (Figure 9B). After 11 days of inhibition, 
very few GFRα1+ cells remained, and after 20 days of inhibition, there were no 
surviving GFRα1+ cells in the seminiferous tubules of these mice (Figure 9A). In 
contrast, there was no change in numbers of Zbtb16+ spermatogonia 5 days of 
treatment, when compared to mice treated with vehicle (Figure 9A). However, 
after 11 days of treatment, there was a significant loss in the numbers of these 
spermatogonia, and after 20 days of treatment, there was a complete loss of 
Zbtb16+ spermatogonia (Figure 9A). To account for any off target effects of NA-
PP1, wild-type mice were also treated with NA-PP1 for 11 days (Figure 9A).  No 
abnormalities in spermatogenesis were detected.   
To quantify these results, we determined the numbers of GFRα1+ or 
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Zbtb16+ As, Apr and Aal spermatogonia per mm
2 of tubule surface. Ret (V805A) 
mice were treated for 5 or 11 days with NA-PP1 or with vehicle. After 5 days of 
inhibition, densities of GFRα1+ As, Apr and Aal spermatogonia were significantly 
reduced to 32%, 15% and 7% of vehicle-treated controls, respectively (Figure 
9B). After 11 days of inhibition, the densities of Zbtb16+ As, Apr and Aal 
spermatogonia were significantly reduced to 12%, 21% and 6% of control, 
respectively (Figure 9B). In addition to quantification of cells, we also measured 
the levels of transcripts encoding Ret, GFRα1 and Zbtb16 (Figure 10). Ret 
mRNA and GFRα1 mRNA testicular levels were similar in control mice. After 
GDNF signaling was inhibited for 20 days, the most pronounced decline was 
observed in Ret mRNA expression (9%), followed by GFRα1 (34%), when 
compared to controls. The expression of Zbtb16 mRNA decreased steadily and 
in a linear pattern to 33% of controls. Taken together, the data demonstrate that 
in the normal adult testis, inhibiting the GDNF signaling complex results in the 
rapid loss of spermatogonial stem cell and/or progenitor spermatogonia, as 
defined by message levels and SSC markers. These data also provide in vivo 
evidence that the RET gene is a direct target of the signal transduction cascade 
associated with GDNF in the testis.  
Inhibition of the GDNF signaling complex for 30 days leads to a loss of all 
functional spermatogonial stem cells in the normal adult testis: 
While figure 10 shows a reduction in message levels of Ret, GFRα1 and 
Zbtb16 after 20 days, these transcripts were still detectable, raising the issue of 
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whether inhibition led to a complete loss of stem and other undifferentiated 
spermatogonia or whether this inhibition only reduced the expression of the stem 
cell markers to levels undetectable by immunocytochemistry. To test the first 
possibility, we injected adult Ret (V805A) and wild-type mice with NA-PP1 for 30 
days and then collected testicular tissue immediately afterwards or after an 
additional 35 days (Figure 11). Ret (V805A) mice were treated for 30 days based 
on data in figure 10, which predicted that this time point was required for the 
complete disappearance of transcripts encoding Ret, GFRα1 and Zbtb16. Thus, 
mice treated for such a prolonged period of time would be lacking in stem and 
progenitor spermatogonia, and therefore, deficient in spermatogenic cells 35 
days later (Figure 12). Our results were consistent with this prediction; the testes 
of NA-PP1-treated Ret (V805A) mice were smaller (55.4 + 4.4 mg) than the 
testes of vehicle-treated mice (217 +9.4 mg (mean + SEM)). In addition, 
examination of ~300 tubules from each of 5 treated wild type mice demonstrated 
that 97± 2.5% (mean + SEM) of the tubules displayed normal spermatogenesis 
(Figure 11 A&B). By contrast, not a single spermatogenic cell was found in the 
seminiferous tubules of the five Ret (V805A) treated mice, leading us to conclude 
that the spermatogonial stem cells were lost during the 30 days of treatment with 
NA-PP1 (Figure 11 C&D).  
A few stem spermatogonia survive after inhibition of the GDNF signaling complex 
for 11 days:  
To elucidate how rapidly the loss of GDNF signaling leads to the loss of 
stem spermatogonia, we treated Ret (V805A) mice and wild-type mice for 11 
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days with NA- PP1 and analyzed their testes 35 days post-treatment. Thirty-five 
days post-treatment, testes of all wild-type mice were morphologically normal, as 
expected (Figure 13 A&B). Seminiferous tubule whole-mounts of Ret (V805A) 
collected 24 hours after the last injection with NA-PP1 revealed the presence of 
very few GFRα1+ cells, all of which were As spermatogonia (Figure 13 C&D). 
Overall, these mice had morphologically normal testes. In contrast, testes of Ret 
(V805A) mice collected 35 days later showed that 97% of the seminiferous 
tubules contained either no spermatogenic cells or only elongate spermatids 
(Figure 14). However, the remaining 3% of the tubules exhibited dense clusters 
of GFRα1+ spermatogonia located in concentrated areas of the seminiferous 
tubule, correlating with areas of active spermatogenesis (Figure 13 E&F). These 
clusters were similar in number (0.24 ± 0.14 clusters/mm2; mean ±SEM) to the 
number of the individual GFRα1+ As spermatogonia on tubules that were 
collected 24 hours after the last of the 11 injections of NA-PP1 (0.46±0.14 
cells/mm2). Taken together, the data suggest that inhibition of the GDNF 
signaling complex for 11 days leads to the loss of approximately 97% of the stem 
spermatogonia. Conversely, restoring GDNF signaling allows the remaining stem 
and undifferentiated spermatogonia to proliferate in an effort to rebuild the tissue.  
Some spermatogonial stem cells or progenitor spermatogonia are lost after 
inhibition of the GDNF signaling complex for 2 days: 
Based on the hypothesis that GDNF promotes self-renewal over 
differentiation of replicating spermatogonial stem cells, we predicted that Ret 
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(V805A) mice treated with NA-PP1 for two days, the approximate duration of the 
one cell cycle, would result in the significant loss of spermatogonial stem cells 
and/or progenitor spermatogonia. To test this hypothesis, Ret (V805A) mice were 
injected with NA-PP1 or vehicle for 2 days and their testes were examined 44 
days later (Figure 15). As expected, the testes of all control mice were normal. 
However, we noted considerable heterogeneity in the histology of tubules of NA-
PP1 treated mice: 25.6% of the tubules were morphologically normal, 9% 
contained Sertoli cells and only a few elongate spermatids, and the remaining 
tubules were missing a generation or two of germ cells, but contained 
spermatogonia and/or preleptotene spermatocytes (Figure 15). These results 
demonstrate that inhibition of the GDNF signaling complex for as few as 2 days 
causes loss of spermatogonial stem cells and/or progenitor spermatogonia.  To 
further understand what was contributing to the loss of As, Apr and Aal 
spermatogonia, we investigated whether the inhibition of the GDNF signaling 
complex for acute periods of time (2 and 3 days) increased the incidence of 
apoptosis by co-staining and quantifying apoptotic undifferentiated 
spermatogonia. However, in both control and treated mice, less than 3% of the 
Zbtb16+ cells expressed the marker of apoptosis, cleaved caspase 3. Overall, 
based on the similar numbers of apoptotic cells in treated and control mice, we 
concluded that apoptosis is not a significant regulator of numbers of GFRα1 
spermatogonia (Figure 16 & 17). Additional studies in the lab have shown that 
this loss of SSCs and progenitor spermatogonia due to inhibition of the GDNF 
signaling complex can be attributed to preferential differentiation of GFRα1+ 
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spermatogonia and suppression of their replication [28].  
DISCUSSION 
 
A unique in vivo approach to investigating the behavior of adult spermatogonial 
stem cells in the mouse: 
  Current approaches to inhibit receptor signaling in the adult, such as 
inducible Cre-mediated recombination, are lengthy, inefficient and irreversible. 
We were the first to use a simple and unique chemical-genetic approach to 
investigate the direct regulation of any adult stem cell population by a single 
growth factor. This approach insures efficient inhibition by coupling a mutated 
ATP binding site of the kinase subunit of the receptor with an ATP competitive 
inhibitor. There are three advantages to this experimental strategy that make it 
particularly relevant to stem cell biology: 1) it involves a completely normal pool 
of stem cells, 2) we can analyze the in vivo response of stem cells to acute and 
prolonged changes in signaling from a specific growth factor, and 3) the inhibition 
is reversible. Using this approach, we were able to investigate the in vivo effects 
of inhibition of the GDNF signaling complex on stem and progenitor 
spermatogonia in the normal adult mouse testes. 
GDNF has previously been shown to be required for the establishment of 
the stem cell pool in vivo in the immature testes and during maturation. However, 
to date, investigators have not addressed how this growth factor regulates SSCs 
and progenitor spermatogonia, and thus, spermatogenesis in the normal adult 
mouse. Our data are the first to prove that this growth factor is required for the 
maintenance of these stem cells in the normal adult testicular environment. We 
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showed that in vivo inhibition of the GDNF signaling complex for only two days 
leads to the loss of stem cells and/or progenitor spermatogonia. This result is in 
contrast to the report that in vitro stem spermatogonial numbers increase when 
cultured in the absence of GDNF for 3 or 6 days [9]. When Ret signaling was 
inhibited for 30 days, we observed a loss in almost all germ cells. In addition, our 
observation that many stem spermatogonia remain after 11 days of inhibition of 
the GDNF signaling complex suggests that GNDF is not solely responsible for 
SSC regulation and that other intrinsic or extrinsic factors may affect the cells 
response to GDNF.  
The current hypothesis in the field states that GDNF promotes self-
renewal over differentiation of replicating stem and other As spermatogonia [1]. In 
support of this hypothesis, we showed that inhibition of GDNF signaling led to 
more of a rapid decline in GFRα1+ spermatogonia when compared to Zbtb16+ 
spermatogonia. Since almost all GFRα1+ spermatogonia co-express Zbtb16, the 
sequential loss of GFRα1 expression, followed by Zbtb16 expression suggests 
that GDNF suppresses differentiation [29]. However, we did not observe an 
increase in the ratio of Apr or Aal spermatogonia to As spermatogonia, suggesting 
that this regulation may be more complex than originally thought.  
Acute inhibition of the GDNF signaling complex leads to a heterogeneous 
testicular environment:  
Our data show that in vivo inhibition of the GDNF signaling complex for 
acute periods of time, 2 to 3 days, results in the loss of some spermatogonial 
stem cells and progenitor spermatogonia, contributing to tubules (8.7%) that are 
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devoid of all but a few elongate spermatids forty-four days post-treatment.  
Additionally, in all but 26% of the remaining seminiferous tubules, we observed 
tubules that lack one or two generations of spermatogenic cells. Based on work 
by Oakberg and Clermont, where they defined the amount of time required to 
complete each phase of spermatogenesis, we estimated that the tubules lacking 
preleptotene spermatocytes, pachytene spermatocytes or round spermatids in 
these animals had lost stem and other undifferentiated spermatogonia around 26 
days, 17 days or 9.2 days after the start of inhibition, respectively [27, 30]. This 
explains why we continued to report the loss of cells after the treatment period 
had ended. Taken together, we interpret this heterogeneous loss of 
spermatogenic cells as evidence of a transient loss of SSCs or progenitor 
spermatogonia, which leads subsequently to the loss of at least one generation 
of more mature spermatogenic cells, showing that inhibition for even 2 days can 
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SUMMARY 
 
Using a unique chemical-genetic approach, we have been able to study 
the consequences of the reversible inhibition of the downstream effects of GDNF 
signaling on stem spermatogonia in a normal adult testis. The experiments 
outlined in this chapter demonstrate that inhibiting the downstream effects of 
GDNF signaling cascade causes a sequential loss of stem cells as identified by 
the SSC markers, GFRα1 and Zbtb16, respectively. In addition, the loss of 
GDNF signaling leads to a loss in SSC message levels, with the most 
pronounced decrease occurring in Ret mRNA levels. We have also shown that 
SSCs and progenitor spermatogonia respond to this loss differentially; where 
some stem cells are lost when the GDNF signaling complex is inhibited for only 2 
days, while others persist for up to 11 days. Due to the reversible nature of our 
model, we were able to demonstrate that once treatment with NA-PP1 had 
ceased and GDNF signaling was restored, the remaining stem cells amplified to 
restore the stem cell pool. In conclusion, these data provide evidence in support 
of the following hypothesis: GDNF is essential in regulating the self-renewal and 
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FIGURE LEGEND 
Figure 1. The Chemical-Genetic approach used to reversibly inhibit the GDNF 
signaling complex . Figure 1A. Normal GDNF signaling: Dimeric GDNF is cross-
linked to two GFRα1 subunits. Together, they bind to two subunits of the receptor 
tyrosine kinase, Ret. Upon phosphorylation of Ret (red star), an intracellular 
signaling cascade is initiated. Figure 1B. Inhibited GDNF signaling: Treatment 
with a competitive ATP inhibitor, NA-PP1, blocks the phosphorylation of mutated 
Ret (blue star), which leads to the inhibition of the GDNF signaling cascade.  
Figure 2. Targeting vector used to introduce the Ret (V805A) mutation into ES 
cells. The targeting vector was constructed using a BAC clone isolated from a 
129J mouse genomic library (RPCI-22). The target sequence was composed of a 
1.4 kb Age I-Hind III fragment containing exons 14 and 15, where a valine to 
alanine missense mutation was introduced at the 805 position of Ret, and placed 
upstream of an FRT-Neo-FRT selection cassette, flanked by loxP sites.  
Figure 3. Determining the minimal dose of NA-PP1 required for inhibition of 
GDNF signaling. In order to determine the minimal dose of NA-PP1 necessary to 
inhibit signaling, Ret (V805A) mice (n=2-3/dose group) were injected for 5 
continuous days with four different doses of NA-PP1. A NA-PP1 dose of 43.7 
mg/Kg was determined to be the minimal dose required for inhibition.  
Figure 4. Example of quantitation of Zbtb16+ and classification as As, Apr or Aal 
spermatogonia. Images captured with a Nikon Eclipse Microscope equipped with 
a cooled CCD camera (QImaging, Surrey, BC, CA) at 20-25X were imported into 
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iVision (Biovision Technologies, Exton, PA) and quantified using their 
morphological differences.  
Yellow: Single cells  
Orange: Paired cells held together by cytoplasmic bridges 
Green: Chains of cells connected by cytoplasmic bridges 
Figure 5. A comparison of the sequence alignments of RET to other kinases that 
have been targeted using a high affinity inhibitor of kinase activity. The shaded 
residues correspond to v-Src residue 338 in the ATP binding pocket of protein 
kinase subdomain V. 
Figure 6. Kinase activity of Ret (V805A) is inhibited by ATP competitive inhibitors. 
HeK293 cells transfected with pRK5 plasmids encoding wild-type RET or RET 
V805A were used to test kinase activity. Phosphorylation of RET was examined 
with the use of immunoblots. Figure 6A: Immunoblot of phospho-RET in cells 
transfected with wild-type Ret and incubated with or without NA-PP1 or 1NM-PP1 
show that there was no effect of the inhibitor on kinase activity of wild-type Ret. 
Figure 6B: Cells expressing Ret (V805A) incubated with or without 100 nM of 
four different ATP competitive inhibitors show that 100 nM of NA-PP1 inhibits Ret 
kinase activity without affecting total Ret. Figure 6C: Dose-dependent effect of 
NA-PP1 on kinase activity of Ret (V805A). Figure 6D: Structures of the ATP 
competitive inhibitors used. 
Figure 7. Body and testis weights of wild type mice (A) and Ret (V805A) mice (B) 
treated for 30 days (left) or 20 Days (right) with vehicle or NA-PP1.  
Data (n=4) are presented as means + SEM. These mice were sacrificed 24 hours 
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post-treatment. The results confirm that there were no off-target effects of drug 
treatment on these mice.  
Figure 8. The effect of NA-PP1 treatment on the kidneys and livers of Ret 
(V805A) mice. Ret (V805A) mice treated with vehicle for 30 days were used as 
controls. NA-PP1 treatment for 30 days revealed no effect on kidney or liver 
histology. Tissues were stained with hematoxylin and eosin (n=5/group), and 
bars are equal to 20 microns (kidney) or 80 microns (liver). Arrows point to 
glomerului in the kidney. 
Figure 9. The in vivo effect of inhibition of the GDNF signaling complex on the 
testicular environment of Ret (V805A) mice. Figure 9A.  Zbtb16+ and GFRα1+ 
spermatgonoia were identified on whole mounts of seminiferous tubules of Ret 
(V805A) mice injected daily with NA-PP1 for 5,11 or 20 days (N=4-6 mice/group). 
Controls included Ret (V805A) mice treated for 20 days with vehicle and wild-
type mice treated for 11 days with NA-PP1 (N=4-6 mice/group). Only a few faintly 
stained GFRα1+ cells were present on the tubules of Ret (V805A) mice treated 
for 5 or 11 days (see arrows), while the density of Zbtb16+ spermatogonia only 
decreased after 11 days. Both GFRα1+ and Zbtb16+ cells were completely 
absent in animals treated with NA-PP1 for 20 days. Figure 9B. Quantitation of 
GFRα1+ (n=3) and Zbtb16+(n=4) As, Apr and Aal spermatogonia in Ret (V805A) 
mice treated with NA-PP1 (white bars) or vehicle (black bars). Data are 
expressed as mean + SEM. 
Figure 10. The in vivo effect of inhibition of the GDNF signaling complex on SSC 
message levels in Ret (V805A) mice. Ret, Zbtb16 and GFRα1 message levels 
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were measured in Ret (V805A) mice that were injected daily with NA-PP1 for 
5,11 or 20 days. (N=4-6 mice/group). Message levels in treated mice were 
compared to Ret (V805A) mice were injected with vehicle for 5 or 11 days. Data 
(mean + SEM; n=5-6/group) are expressed as the numbers of molecules of each 
transcript divided by numbers molecules of 18S rRNA in the same sample. The 
inhibition of GDNF signaling resulted in the progressive loss of Ret, GFRα1 and 
Zbtb16 message levels, with the most pronounced decrease noticed in Ret 
message levels. 
Figure 11. The in vivo effect of inhibiting the GDNF signaling complex for 30 days 
on the testicular environment of Ret (V805A) mice. Figure 11 A&B. The testicular 
histology of wild-type treated for 30 days with NA-PP1 and testes collected 35 
days thereafter, (N=5 mice). Figure 11 C&D. The testicular histology of Ret 
(V805A) treated for 30 days with NA-PP1 and testes collected 35 days thereafter, 
(N=5 mice). The white arrowheads in panels B and D point to Sertoli cell nuclei, 
bar = 20 microns. 
In panel B: white arrows = spermatogonia 
Black & white arrowhead = the nuclei of a pachytene spermatocyte  
Black & white arrow = a round spermatid  
White & black arrowhead = a nucleus of an elongate spermatid  
Figure 12. Differential sensitivities of SSC resulting from inhibition of GDNF 
signaling. Top panel: This figure depicts maturation depletion and repletion after 
the loss of many spermatogonial stem cells, which eventually lead to the loss of 
mature spermatogenic cells over time. The yellow boxes indicate the types of 
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spermatogenic cells lost with increasing time, where each series of boxes 
represent ~8.6 days. Bottom panel: This figure depicts maturation depletion after 
the loss of all spermatogonial stem cells, which eventually leads to the loss of all 
germ cells over time. The pink boxes indicate the types of spermatogenic cells 
lost with increasing time.  
Figure 13. The in vivo effect of inhibiting the GDNF signaling complex for 11 days 
on the testicular environment of Ret (V805A) mice. After inhibiting the GDNF 
signaling complex for 11 days, the remaining stem spermatogonia begin to 
rebuild the stem cell pool. The histology is representative of testes of Ret 
(V805A) and wild type mice treated for 11 days, and collected either 1 or 35 days 
post treatment (n=4 mice/group), bar = 20 microns. 
Panels A, C & E: one micron thick cross sections of seminiferous tubules 
Panels B, D & F: whole mounts of tubules immunostained for GFRα1+ 
spermatogonia Arrowheads = rare and weakly stained GFRα1+ As 
spermatogonia  
Black & white arrowhead= spermatocyte  
White arrow= 10 GFRα1+ Aal spermatogonia cells in a chain, indicative of dense 
patches of spermatogonia 
Figure 14. The predominant phenotype associated with the in vivo inhibition of 
the GDNF signaling complex for 11 days on the testicular environment of Ret 
(V805A) mice. 
Majority to the tubules in mice treated with NA-PP1 and testes examined 35 days 
thereafter had lost almost all spermatogonial stem cells, lacking spermatogenic 
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cells and elongate spermatids, bar = 20 microns (N=4). Panel A: low power 
image of a NA-PP1 treated Ret (V805A) mouse of a testis cross section. Panel B 
& C: testicular cross-sections representing the 97% rate of maturation depletion 
in these animals, where only Sertoli cells (arrow head, panel B) and elongate 
spermatids (arrow head, panel C) were remaining. 
Figure 15. The acute in vivo effect of inhibiting the GDNF signaling complex for 2 
days on the testicular environment of Ret (V805A) mice. A high degree of 
diversity was observed in Ret (V805A) mice in which GDNF signaling was 
inhibited for only 2 days and testes collected 44 days later. Bar = 20 microns 
(N=4). Panel A: shows normal spermatogenesis containing all spermatogenic cell 
types (White arrows = spermatogonia or preleptotene spermatocytes). Panel B: 
shows a cross-section lacking pachytene spermatocytes. Panel C: shows a 
cross-section lacking round spermatids. Panel D: shows a cross-section lacking 
elongate spermatids (White& black arrowheads). Panel E:  shows a cross-
section containing only Sertoli cells and elongated spermatids. Panel F: shows a 
cross-section lacking both round spermatids (Black & white arrows) and 
pachytene spermatocytes (Black & white arrowheads). 
Figure 16. Zbtb16+ and cleaved caspase 3+ spermatogonia in Ret (V805A) mice 
treated with Na-PP1. The inhibition of the GDNF signaling complex does not lead 
to an increase in apoptosis in Ret (V805A) mice. Majority of cells expressing 
cleaved caspase 3 did not co-express Zbtb16, making these co-stained 
detectable, but rare. Figure 16 A. The white arrow points to the sole apoptotic cell 
(red) at the end of a chain of Zbtb16+ cells (green). Image show cells in a 2.3 
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micron section of a whole mount imaged by confocal microscopy using a 25X 
objective. Figure 16 B. The left panel shows a chain of 4 Aal spermatogonia co-
stained for Zbtb16 (green) and cleaved caspase 3 (red). Middle panel show just 
the cleaved caspase 3+ cells (red). The right panel shows just the Zbtb16+ cells 
(green). Image show cells in a 2.3  micron section of a whole mount imaged by 
confocal microscopy using a 40X objective.  
Figure 17. The in vivo effect of inhibiting the GDNF signaling complex on 
apoptosis. Treating Ret (V805A) mice for 2 and 3 days with NA-PP1 does not 
lead to an increase incidence of apoptosis. Because cells co-stained for Zbtb16 
and cleaved caspase 3 were rare in Ret (V805A) mice injected with Na-PP1 or 
vehicle, cells expressing only cleaved casapse 3 were quantified. Data are 





























































































































	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  






































































































































































































































































































CHAPTER 3: Understanding the role of GDNF in regulating stem and progenitor 
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ABSTRACT 
Chapter 2 proves that GDNF is essential in maintaining spermatogonial 
stem cells (SSCs) and progenitor spermatogonia in the adult mouse testis. If this 
growth factor has a similar function in men, we hypothesize that GDNF 
expression and the distribution of its receptor, GFRα1, would be similar in the 
testes of normal men, when compared to mice and rats, whose SSCs are GDNF-
dependent. Our results show that GDNF mRNA levels in mice and men are 
similar, while GDNF protein concentrations in the total testicular fluid (TTF) of 
men (1800 pg/ml) is 36% of that of mice. Because SSCs are situated on the 
basal side of the blood-testis barrier, the fluid that surrounds these stem cells is 
continuous with the testicular interstitial fluid (TIF). Thus, in an effort to be 
thorough, we compared GDNF protein concentrations in TIF, TTF, and 
seminiferous tubule fluid (STF). Since the collection of TIF is difficult in mice and 
men, we collected this fluid from rats using a previously validated protocol and 
compared GDNF levels in TIF, STF and TTF, collected from the same animals. 
Results show that GDNF protein levels in rat TTF is identical to humans, but is 
substantially lower in rat TIF. This suggested that GDNF could be essential in 
regulating human SSCs and progenitor spermatogonia. To further test this 
hypothesis, we compared GDNF mRNA levels in normal human testes with 
levels in testes of men who were diagnosed as being infertile due to the lack of 
spermatogenic cells. Our results showed that infertility was associated with an 
80% decrease in expression of this transcript. To address whether reduced 
GDNF expression in individuals with the Sertoli-cell-only (SCO) phenotype was 
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due to a complete state of hypo-function or a specific deficiency in their Sertoli 
cells, we measured transcripts encoding two Sertoi cell products, kit ligand and 
clusterin. Expression of neither transcript was reduced in these SCO testes. As 
GDNF regulates the numbers of spermatogonial stem cells and progenitor 
spermatogonia in the adult mouse testes, we next tested the hypothesis that 
numbers of GDNF responsive spermatogonial stem cells and progenitor 
spermatogonia, as identified by expression of GFRα1, were higher in mice and 
similar in humans and rats. Results showed that numbers of these cells were 
highest in humans, intermediate in rats and low in mice. However, in all three 
species, areas of tubules with relatively high numbers of GFRα1+ cells were 
interspersed with areas with none.  To verify the localization of GFRα1 to human 
SSCs and progenitor spermatogonia, we co-stained these seminiferous tubules 
with UCHL1, an established marker for Ad, Ap and Type B spermatogonia. Our 
results verified the localization of GFRα1 to a portion of the UCHL1+ cells, 
indicating their ability to bind to GDNF. Taken together, our data support the 
hypothesis that as in rodents, GDNF is essential for maintaining the population of 
human SSCs and progenitor spermatogonia. These data are the first indication 
that depressed GDNF expression may lead to loss of SSCs, and consequently 
human male infertility. This finding opens up the possibility that clinical 
procedures to increase GDNF concentration in individuals with SCO testes with a 
few remaining SSCs might aid in rebuilding the numbers of these stem cells, and 
increase the possibility that sufficient sperm are generated either for natural or 
assisted reproduction.  
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INTRODUCTION 
Understanding the regulation of SSCs and progenitor spermatogonia in 
humans is central to understanding male fertility. This regulation is dependent on 
the balance between SSC self-renewal and their production of transit-amplifying 
progenitor spermatogonia, which replicate and give rise to differentiated 
spermatogonia [1]. Most of our knowledge regarding the regulation of 
mammalian SSCs and progenitor spermatogonia comes from studies of rodents. 
In the mouse, SSCs exist as a subpopulation of As spermatogonia, which are 
sparsely distributed along the length of the seminiferous tubule. These SSCs 
asymmetrically divide to self-renew or give rise to Apr spermatogonia [2, 3], which 
then undergo clonal expansion through mitotic divisions to generate chains of Aal 
spermatogonia. These cells give rise to type A and B spermatogonia, which are 
irreversibly committed to the ultimate formation of spermatids [2]. In contrast to 
the mouse, humans and other primates have two functional populations of SSCs 
(Adark and Apale). Adark  spermatogonia represent the reserve stem cells, and Apale  
spermatogonia represent the mitotically active stem cells that sustain 
spermatogenesis [4-7]. Unlike the mouse, progenitor spermatogonia in humans 
replicate only once before giving rise to B spermatogonia [8]. This suggests that 
for humans to produce the numbers of sperm required for fertility, the numbers of 
sperm produced per gram of testis are not substantially different in men and 
mice.  
In the mouse, GDNF has been shown to be required for maintaining and 
expanding SSCs in vitro. For instance, work in our lab has shown that increasing 
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the concentration of GDNF around seminiferous tubules in vitro stimulated the 
proliferation of SSCs and progenitor spermatogonia [9]. Additional in vivo studies 
have shown that GDNF is essential for establishing the stem cell pool in the 
immature testis, and for maintaining these cells in the normal adult testis [9-11]. 
Using a specific mouse model, we were able to confirm this in the context of a 
normal adult testicular environment and demonstrate that GDNF is a primary 
regulator of both the replication and differentiation of SSCs and progenitor 
spermatogonia [9, 12]. When we inhibited GDNF signaling for 2 or 3 days, a 
significant decrease in replicating As spermatogonia was observed, followed by 
differentiation, generating Type A1 spermatogonia [12]. This loss of SSCs and 
progenitor spermatogonia continued with increasing periods of inhibition of 
GDNF signaling, until the testes were devoid of stem and progenitor 
spermatogonia [9].   
As previously mentioned, most of our understanding of the regulation of 
SSCs is based on studies of the mouse. There is limited information on how 
GDNF is involved in regulating stem and progenitor spermatogonia in humans. 
Studies have shown that as in the mouse, Sertoli cells in humans 
transcriptionally express GDNF [13, 14]. However, it remains to be shown 
whether GDNF levels in the normal human testes are adequate to stimulate 
replication or suppress differentiation of SSCs or progenitor spermatogonia. In 
addition, no one has directly compared the expression of GDNF in situ in the 
testicular environment of fertile vs. infertile men. Neither has there been a 
determination of whether altered expression of GDNF is a characteristic of 
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infertility per se, or whether it is only occurs when testes exhibit the Sertoli cell-
only (SCO) phenotype and have significantly reduced numbers of 
spermatogonial stem cells. This chapter aims to resolve these gaps in our 
knowledge. We began by comparing fertile humans to fertile mice and rats, in an 
effort to understand the level of similarity in GDNF regulation between these 
mammalian species. Secondly, in an effort to understand the role of GDNF in 
supporting human fertility, we compared GDNF message levels in fertile and 
infertile men. We also address the distribution of GFRα1, the ligand-binding 
domain of the GDNF receptor in the human testis, and compare it to the 
distribution in rodents. In the mouse testis, GFRα1 is expressed exclusively by 
spermatogonial stem cells and progenitor spermatogonia [12]. While there are 
molecular similarities between these cell types in mice and men, varying reports 
indicate that GFRα1 localizes to different cell types in the human testis [15]. 
Davidoff and colleagues report that this receptor subunit is expressed by human 
Leydig and Sertoli cells, while others report that GFRα1 localizes to a subset of 
Ad and Ap spermatogonia [13, 16]. The studies outlined in this chapter also 
address this discrepancy.  
 Based on the similarities between human and mouse spermatogenesis, 
we have used comparisons to the rodent models to further our understanding of 
human fertility [7]. Specifically, we hypothesize that the concentrations of GDNF 
in the human, mouse and rat testes are similar and thus, the level in the human 
testis is sufficient to be an important regulator of SSCs and/or progenitor 
spermatogonia. If this is true, then we hypothesize that GDNF mRNA would be 
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substantially reduced in infertile men, whose testes were lacking in stem cells. 
Lastly, we hypothesize that the same cell types in mice, rats and men express 
GFRα1, the ligand binding subunit of the GDNF receptor. To test our 
hypotheses, GDNF message and protein levels were measured and compared in 
fertile mice, men and rats. In addition, we compared GDNF mRNA levels in 
human testis with normal spermatogenesis, to individuals who presented with 
SSCs but failed to produce sperm due to spermatogenic arrest, and individuals 
who presented with rare SSCs, resulting in a Sertoli cell-only phenotype. 
Although reduced GDNF expression is not noted in germ cell-deficient mice, we 
chose to measure GDNF mRNA levels in individuals with SSCs but reduced 
numbers of spermatogenic cells due to maturation arrest for a thorough 
comparison [17]. Lastly, distributions and relative numbers of GFRα1+ cells on 
seminiferous tubules were compared between species. To further define the 
population of human spermatogenic cells GFRα1 was localized to, we co-stained 
with another marker for human stem and progenitor spermatogonia, UCHL1. The 
findings outlined in this chapter are unique because they represent the first direct 
comparison of GDNF message levels in testes of infertile men to normal fertile 
men. Taken together, our data further support the hypothesis that GDNF is an 
important regulator of human spermatogonial stem cells and progenitor 
spermatogonia and that reduced GDNF expression reflects a specific deficit in 
the function of Sertoli cells.	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MATERIALS AND METHODS 
Tissue Collection:  
 Whole human testes were collected from beating-heart organ donors by 
the organ transplant center of the University of Pittsburgh Medical Center. Testis 
biopsies were collected by Dr. Peter Schlegel as part of standard clinical care 
during microdissection testicular sperm extraction at Weill Medical College of 
Cornell University. Collection and analysis of human testes was approved by the 
Institutional Review Boards of Weill Medical College of Cornell University, The 
University of Pittsburgh Medical School and the Johns Hopkins Bloomberg 
School of Public Health.  
Collection of Testicular Fluids: 
Human testis fluids were collected by percutaneous aspiration from 
patients who were undergoing vasectomy reversals and who had given informed 
consent for the procedure [18]. Human blood was collected by venipuncture of 
the same patients. All patient identifiers had been extracted from the samples 
prior to our use. Collection of human testis fluid and blood was conducted by Jon 
Jarrow, M.D. and this collection and our analyses were approved by the 
Institutional Review Boards of the Johns Hopkins University School of Medicine 
and the Bloomberg School of Public Health. Seminiferous tubules and testis 
fluids were collected from mature male mice (Bl6SJL/J genetic background) and 
from Sprague Dawley rats. Collections of tissues and fluids from mice and rats 
were approved by the Institutional Animal Care and Use Committee of Johns 
Hopkins University. Seminiferous tubule and interstitial fluid was collected from 
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60-day old Sprague Dawley rats as previously described by Turner and 
colleagues [19]. Briefly, two small holes were made on the basal end of mature 
rat testis and interstitial fluid expressed from the testis by centrifugation at 54XG 
for 15 minutes. The testes were then decapsulated and washed in three separate 
baths of PBS. After blotting of the tubules with a gauze pad, the tubules were 
macerated by expressing them through a 3 cc syringe into a polycarbonate 
centrifuge tube. Seminiferous tubule fluid was expressed from the tubules by 
centrifugation at 10,000 x g at 4°C for 30 minutes. Total testicular fluid was 
recovered from mice and rats by centrifugation of macerated tubules at 10,000 
rpm at 4°C for 30 minutes, to separate the fluid from the tissue. To remove 
debris, all fluids were collected and re-spun for an additional 10 minutes at 
10,000 rpm at 4°C. Serum was separated from trunk blood by allowing the blood 
to clot for 30minutes-1hr, and then centrifuged at 3,000 rpm at 4°C for 
15minutes.  
Tissue Preparation and Fixation for Immunohistochemistry:  
Normal adult mouse and rat testes were stripped of the tunica, releasing 
compacted seminiferous tubules. These tubules were manually separated in 
PBS, fixed for 2 hours in 4% paraformaldehyde at room temperature and washed 
in PBS (four times, 30minutes/wash). Human testicular tissue from beating heart 
donors was obtained from the University of Pittsburgh and transported on ice in 
Belzer UW cold storage solution (Bridge to Life, Columbia, SC) within ~24- 36 
hours of being harvested. Human tubules were processed identically to rat and 
mouse tubules, with the exception of being manually separated in pre-warmed 
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DMEM/F-12 (Life Technologies). Results with these tubules were confirmed 
using human seminiferous tubules that were immediately fixed in Pittsburgh and 
then shipped to Baltimore, in Belzer UW cold storage solution and on ice.  
Message Level Detection:  
Due to an increased level of sensitivity, digital PCR was used to detect 
GDNF message levels in the human and mouse. RNA was isolated from tissue 
using the Qiagen RNeasy Mini kit (Qiagen, Valencia, CA) and cDNA was 
synthesized using the SuperScript III First Synthesis kit (ThermoFisher Scientific, 
Waltham, MA), using random hexamers as primers (InVitrogen, Carlsbad, CA). 
Digital PCR was conducted using the Life Technologies QuantStudio 3D System 
and Taqman real time PCR assays (InVitrogen). 18S rRNA, DDX4, kit ligand and 
clusterin mRNA were assayed using Taqman assays and the StepOnePlus Real-
Time PCR System (ThermoFisher Scientific,Waltham, MA). A standard curve of 
cloned plasmids encoding 18S rRNA, DDX4, kit ligand or clusterin mRNA was 
run with each assay of these transcripts.	  All data were normalized to the amount 
of 18S rRNA in each sample. Negative controls included cDNA samples 
synthesized without reverse transcriptase and PCR reactions run with water 
instead of cDNA. 	  
Protein Level Detection:	  	  	  	   	    
	  	  	  	  	  	  	  	  	  GDNF protein was measured in human, mouse and rat testicular fluid and 
rat seminiferous tubule and interstitial fluids using the GDNF Emax 
ImmunoAssay System (Promega, Madison, WI). Testicular fluids in humans and 
mice and all fluids in the rat were diluted to at a 5:95 (fluid: buffer) dilution with 
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sample 1X buffer (provided in the kit). OD was measured using a fluorescent 
plate reader (DT 800 Multimode detector (Beckman Coulter, Sykesville, MD). 
Serum in humans, mice and rats were measured at a 10:90 dilution (fluid: sample 
1X buffer). A standard curve (15.625 pg/ml to 1 ng/ml of GDNF) was run in 
duplicate in with each assay. Analysis of standard curves from four independent 
assays demonstrated that the lowest standard that produced a response in the 
assay different from no GDNF was a concentration of 31.25 pg/ml GDNF, as 
determined by the means, standard deviation of the means and SEM. 
GFRα1 Immunohistochemistry in whole –mounts of seminiferous tubules of 
fertile humans, mice and rats:  
4% PFA-fixed tubules were blocked with PBS and 1% BSA (PBS-B) for 1 
hr at RT in netwells in a 12-well plate. The tubules were washed with PBS once 
for 5 minutes and incubated overnight with primary antibody (1: 100, Goat anti-rat 
GFRα1, R&D systems, catalog # AF560) PBSB (1% BSA per 100ml PBS) at 
4°C. The next day, the tubules were washed 6X, 15 minutes/wash in PBSBT 
(0.1% Trition X-100 in 1% BSA per 100ml PBS) and incubated overnight at 4°C 
with secondary antibody (200ul/well, 1:500 Alexa 488-anti goat IgG) in PBSBT. 
On the last day, the tubules were washed 6X for 15 minutes each with PBSBT 
and mounted as described below. Whole mounts of seminiferous tubules were 
optically sectioned (2.3 µm) using a Zeiss LSM 710 Confocal Microscope and 
GFRα1+ cells examined. Same settings were used for imaging negative controls 
(isotype control IgG or without primary antibody). Brightness and contrast of 
images were adjusted so that GFRα1+ cells in all species and GFRα1+ cells co-
	   105	  
stained with UCHL1+ in humans had the same brightness. 
Human UCHL1 immunohistochemistry in whole-mounts of seminiferous tubules 
of fertile men:  
4% PFA fixed seminiferous tubules were washed with PBS once for 5 
minutes and incubated overnight with primary antibody (1:1000, Biogenesis, 
catalog # 7863-0507) in PBSB at 4°C. The next day, the tubules were washed 6X 
for 15 minutes each in PBSBT and incubated overnight at 4°C with Donkey anti-
Rabbit IgG (H+L) Alexa Fluor 488 conjugate (1:200, Invitrogen Molecular Probes, 
catalog # A-21206) in PBSBT. On the last day, the tubules were washed 6X for 
15 minutes each with PBSBT and mounted in VectaShield with DAPI (Vector 
Laboratories, catalog # H-1200). Tubules were examined by confocal microscopy 
as described above.  
Human UCHL1 and GFRα1 immunohistochemistry in whole-mounts of 
seminiferous tubules of fertile men:  
4% PFA fixed human seminiferous tubules were washed with PBS once 
for 5 minutes and incubated overnight with UCHL1 primary antibody (1:1000; 
Biogenesis, catalog # 7863-0507) and GFRα1 primary antibody (1:500, R & D 
systems, catalog # AF560) in PBSB at 4°C. Controls were incubated with non-
immune IgG. The next day, tubules were washed 6X for 15 minutes each in 
PBSBT and incubated overnight at 4°C with Donkey anti-Rabbit Alexa Fluor 488 
(1:200, IgG (H+L), Invitrogen Molecular Probes, catalog # A-21206) and Donkey 
anti-goat IgG Alexa Fluor 546 (H+L) conjugate (1:500, IgG (H+L), Invitrogen 
Molecular Probes, catalog # A-11056) in PBSBT. On the last day, the tubules 
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were washed 6X for 15 minutes each with PBSBT and mounted in VectaShield 
with DAPI (Vector Laboratories, catalog # H-1200). Tubules were examined by 
confocal microscopy as described above.  
Mounting Seminiferous tubules: 
Seminiferous tubules were mounted on slides by placing four drops of 
clear nail polish on the slide. The purpose of this is to create raised edges to 
prevent the cover slip from crushing the tubules. A few drops (2-3) of PBS are 
placed on the slide to which the tubules are added and separated using forceps. 
Any excess PBS was soaked up gently via a Kimwipe and a drop of Vectashield 
was placed to coat the tubules. The coverslip was placed and secured by sealing 
the edges with clear nail polish. The slides were allowed to dry for at least 20 
minutes before observing.   
Quantitation of GFRα1+ spermatogonia in fertile humans and mice:  
Human, rat and mouse seminiferous tubules were imaged on a Zeiss 710 
confocal microscope, under 25X magnification. Tubules were analyzed by 
scanning along the length of the tubules and 2.3 uM (1 Airy unit) thick optical 
sections captured with a 46.5 pinhole. The image within the parameter was 
categorized as LOC (lots of cells), FC (few cells) or NC (no cells) as described 
below. Then the tubule was moved to the next section to be analyzed and 
quantified. This was done till the entire tubule was analyzed and the process was 
repeated for the next tubule to be quantified. Cells that were faintly and intensely 
stained were counted, as long as the continuous outline of the cell was stained. 
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GFRα1+ counts: Lots of Cells (LOC): Few Cells (FC): No Cells (NC) 
Mouse > 4 GFRα1+ cells 1-4 GFRα1+ cells No GFRα1+ cells 
observed in the 
microscopic field 
Human > 16 GFRα1+ cells 1- 6 GFRα1+ cells No GFRα1+ cells 
observed in the 
microscopic field  
 
Statistical Analysis: 
  Statistical analyses on message levels, protein levels, and GFRα1 
quantification was performed using GraphPad Prism Version 6.0 (GraphPad 
Software, La Jolla, CA). Data obtained for message and protein levels were 
analyzed by ANOVA or an unpaired t-test using Welch’s correction. Statistically 
significant differences were defined as P< 0.05.  
RESULTS 
GDNF Message levels in testes of normal men and mice: 
           The concentration of GDNF mRNA levels in normal human testes has not 
been evaluated. However, we predict that if GDNF plays a similar role in 
regulating SSC numbers in human and mouse testes, levels of GDNF mRNA 
would be similar. Our initial attempts to measure GDNF message levels relied on 
quantitative RT-PCR. However, we were unable to detect transcript levels in our 
human samples because of the relative insensitivity of the human GDNF assay. 
We were able to overcome this challenge by using the novel and more sensitive 
technology of digital PCR to measure the expression of GDNF mRNA in testes of 
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fertile men and mice. Our comparison revealed that GDNF mRNA levels are 
similar in human and mouse testes (Figure 1). Controls included replacement of 
the sample with water or with testis RNA that was subjected to conditions for 
cDNA synthesis without the addition of reverse transcriptase. The negative 
controls were identical to background in the assay.  
GDNF protein levels in total testes fluid of normal humans and mice:  
  While GDNF mRNA levels in mice and humans did not differ, it was 
possible that there were significant differences between the translational 
regulation of GDNF synthesis or in the turnover of GDNF protein in these two 
species. Therefore, we used a two-antibody enzyme-linked immunoassay to 
measure GDNF in mouse and human total testicular fluid. As a control, we also 
measured GDNF protein levels in human and mouse serum (Figure 2). Results 
revealed that GDNF protein levels in total testis fluid in human testes (~1800 
pg/ml) were 64% of those of the mouse (~5200 pg/ml) (Figure 3), which was a 
statistically significant difference.  In contrast, GDNF levels in human and mouse 
serum were below the sensitivity of the assay. 
GDNF protein levels in total testicular fluid, interstitial fluid and seminiferous 
tubule fluid of rats: 
Growth factors in seminiferous tubule fluid are separated from contact with 
the basal compartment of the tubule by the blood-testis-barrier, which isolates 
the SSCs and progenitor spermatogonia from GDNF and other growth factors 
present in the adluimal compartment , which contains seminiferous tubule fluid 
(STF). Thus, the SSCs are directly exposed to the fluid in testicular interstitial 
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compartment (TIF). To understand the subtleties in GDNF concentration in these 
three distinct types of testicular fluid environments, we isolated these fluids and 
individually measured GDNF protein concentrations. To overcome the challenge 
of collecting interstitial fluid in mice and men, we deferred to the use of Sprague 
Dawley rats. It has previously been shown that GDNF mRNA and protein are 
positively correlated in the rat, and that GDNF regulates As replication and 
differentiation in vitro [20-22]. TIF was collected from the testes of 4 mature male 
rats using an established protocol [19], and GDNF protein levels in this fluid were 
compared to levels in seminiferous tubule fluid (STF) and total testicular fluid 
(TTF), collected from the same animals. Results show that the concentration in 
rat STF (~4200 pg/ml) is 5-fold higher than in TIF (~800 pg/ml) (Figure 4). 
However, the concentration of GDNF in total testis fluid of rats (~2600 pg/ml) is 
similar to the concentration in humans (~1800 pg/ml) (Figure 3). However, when 
compared to mouse concentrations (~5200 pg/ml), the GDNF concentration in 
TTF of rats is ~50% lower (Figure 3). Taken together, these data show that 
GDNF concentrations in the testicular interstitial fluid are significantly lower than 
in total testicular fluid, but still sufficient to support the SSC population in rats. 
Secondly, based on similar TTF protein concentrations in rats and men, we 
hypothesize that the GDNF concentrations in TIF of men are rats are similar, 
and, thus, the concentration in human TIF is adequate for sustaining the SSC 
pool. 
The comparison of GDNF, DDX4, kit ligand and clusterin mRNA expression in 
the testes of fertile and infertile men: 
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The long-term goal of this research is to test the hypothesis that GDNF is 
required for the in vivo maintenance of human SSCs. If true, the testicular GDNF 
mRNA concentration would be substantially lower in a subset of infertile men 
diagnosed with the Sertoli cell-only phenotype, when compared to fertile men or 
infertile men whose testes contained SSCs, but who were diagnosed with 
azoospermia due to maturation arrest of spermatogenesis. We therefore 
compared GDNF mRNA levels in fertile human testes, testes of men who were 
infertile due to maturation arrest and men whose testes exhibited an SCO 
phenotype. A complete description of the samples analyzed and the diagnosis 
provided by Brian Robinson, MD, Department of Pathology, Weill Cornell Medical 
College, can be found in Table 1. To test this hypothesis, we used digital PCR to 
compare the expression of GDNF mRNA in these three distinct groups of men. 
GDNF mRNA levels were similar in fertile men and in the testes of men who 
were infertile due to maturation arrest of spermatogenesis. However, 
measurement of GDNF message levels in SCO individuals were significantly, 
80% and 87%, lower when compared to men with normal testes or NOA men 
with maturation arrest, respectively (Figure 5A). To address the question of 
whether reduced GDNF expression in individuals with the SCO phenotype was 
due to a complete state of hypo-function or a specific deficiency in their Sertoli 
cells, we measured	  transcripts encoding two other Sertoi cell products, kit ligand 
and clusterin. Expression of neither transcript was reduced in these SCO testes 
(Figure 5 C&D). Instead, the expression of both transcripts were significantly 
increased in SCO testes, possibly reflecting a higher percentage of RNA of 
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Sertoli cell origin due to the lack of germ cells in these samples. This lack of 
germ cells in the SCO testes was confirmed by the almost complete absence of 
DDX4 mRNA, a marker of germ cells. (Figure 5B). Thus, the data suggest that 
decreased GDNF expression observed in individuals with the SCO phenotype 
might be attributed to a specific dysfunction in their Sertoli cells, rather than a 
complete state of hypo-function. 
Expression of GFRα1 in the adult testis of normal humans, mice and rats: 
GFRα1, a well-established marker for mouse SSCs and progenitor 
spermatogonia is expressed in the adult human testis [15, 16, 23]. While its 
expression has previously been localized to Ad, Ap, B spermatogonia in cross-
sections of human seminiferous tubules, neither the relative numbers of these 
cells nor their distribution along the length of human seminiferous tubule have 
been evaluated. However, if GDNF is the primary regulator of the numbers of 
GFRα1+ spermatogonia, based on the trend observed in GDNF protein levels, 
the numbers of these cells in mice should be higher than in men, but numbers in 
men and rats should be similar. We used whole mount immunocytochemistry of 
mature human, rat and mouse tubules to assess this prediction. Post-pubertal 
human organ donors with normal spermatogenesis and mature male mice and 
rats were used for immunohistochemical analysis; two of the human donors were 
between 25-49 years of age. Results show that the density of GFRα 1+ 
spermatogonia was substantially higher in the seminiferous tubules of all four 
men, when compared to mice and rats (Figure 6). However, scanning across 
tubules revealed a similar pattern of areas of high and low densities of GFRα1+ 
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cells in human and mouse tubules (Figure 6 A-F). Our results show that ~65% of 
each mouse and human tubule was covered with high density patches of 
GFRα1+ spermatogonia, and the rest of the tubule contained low densities or the 
complete lack of these cells (Figure 7). In the rat, we observed a more consistent 
pattern of chains of cells distributed along the span of the tubule (Figure 6 G-I). 
Human seminiferous tubules fixed immediately after acquisition, but processed 
for immunocytochemistry at a later date displayed identical pattern of staining 
(data not shown).  
Expression of GFRα1+ & UCHL1+ spermatogonia in the seminiferous tubules of 
normal fertile men:  
  To understand whether this patchy distribution of spermatogonia was 
reproducible when a different marker was used to identify the cells, we stained 
seminiferous tubules from a fertile individual for UCHL1, a spermatogonial 
marker [15]. Results revealed a similar pattern of high and low densities of 
UCHL1+ spermatogonia (Figure 8). We next co-stained human seminiferous 
tubules with GFRα1 and UCHL1 to verify that GFRα1 was indeed localizing to 
SSCs and progenitor spermatogonia. Immunohistochemical analysis of tubules 
processed from one individual show co-stained cells (Figure 9). To make it easier 
to visualize the density of GFRα1+, a black and white version is also provided in 
the figure. From this, we can conclude that a population of human 
spermatogonial stem cells and/or progenitor spermatogonia express the ligand 
binding subunit of the receptor needed for a response to GDNF.  
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DISCUSSION 
Expression of GDNF mRNA and protein in the testes of normal humans, mice 
and rats:   
These studies were grounded in the hypothesis that if GDNF regulates the 
numbers of human SSCs and progenitor spermatogonia, as it does in the mouse 
and rat, then the human testis expression of GDNF mRNA and concentration of 
GDNF protein in testes fluids would be similar to that of rodents and sufficient to 
trigger the GDNF signaling cascade. Digital PCR, a highly precise method, 
revealed that GDNF mRNA levels are almost identical in human and mouse 
testes. This motivated us to compare GDNF protein concentrations in the 
testicular fluids of humans, mice and rats, and in the interstitial and seminiferous 
tubule fluids of rats. Our results showed that GDNF proteins levels are 2.7-fold 
higher in the mouse vs. man. This could be due to possibility that translation of 
GDNF mRNA is more efficient in the mouse or perhaps, that the protein is 
cleared more rapidly from the human testis. Nonetheless, the fact remains that 
the concentration of GDNF in human total testicular fluid is almost identical to its 
concentration in rat total testicular fluid. This suggests that as in rodents, the 
concentration of GDNF surrounding human SSCs is sufficient to act as a mitogen 
and cell survival factor for these stem cells.  
GDNF stimulates target cells through a single high-affinity binding site on 
GFRα1, the ligand binding subunit of the GDNF receptor. The affinity of this 
binding reaction as estimated by Kd is 11 pM [24, 25]. Thus, when viewed in the 
context of the kinetics of binding of GDNF to its receptor, the concentration of 
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GDNF in the human testis fluid (60 pM) is sufficient to drive the occupancy of a 
substantial percentage of GDNF receptors on SSCs and progenitor 
spermatogonia, thereby initiating the downstream effects of GDNF signaling in 
these cells. However, we acknowledge that Sertoli cells secrete many proteins 
vectorially, resulting in varying protein concentrations in different fluids of the 
testis, like the seminiferous tubule fluid and interstitial fluid [26-31]. Therefore, it 
is possible that the GDNF concentration in human interstitial fluid, which is 
continuous with the fluid that bathes SSCs and progenitor spermatogonia, differs 
from its concentration in the total testicular fluid, which is a mixture of the two 
testis fluids. Because collecting TIF and STF was not feasible in mice and men, 
we examined these fluids collected from rat testes, for which there is a well-
established protocol. For a complete comparison across species, we also 
measured GDNF concentration in total testicular fluid from the rat. The results of 
this experiment revealed: (1) GDNF concentration in total testis fluid of rats is 
nearly identical to that of humans, and (2) the concentration of GDNF in testicular 
interstitial fluid in the rat (27pM) is 40% lower than in the STF. Due to the striking 
similarity in GDNF concentrations in the total testicular fluid of men and rats, we 
extrapolated relationships between fluids in the rat as a model to understand the 
consequences of GDNF protein levels on SSCs and progenitor spermatogonia in 
humans. Inherent in this thought are two underlying assumptions: 1) the 
concentrations of GDNF mRNA and protein in the human testes are positively 
correlated as they are in the rat [22], and 2) as shown in the rat, we estimate the 
	   115	  
concentration of GDNF in TIF of a fertile man is 31% of its concentration in TTF, 
or 19pM.  
Evidence that GDNF is necessary for the maintenance of human spermatogonial 
stem cells and progenitor spermatogonia: 
The estimates of GDNF concentration in TIF of the fertile human testis 
have important implications in understanding the role GDNF has in contributing 
to infertility. We predict that the 80% decrease in expression of GDNF mRNA in 
the human SCO testis translates to a GDNF concentration in the TIF of these 
infertile men of approximately 2pM, a concentration, which is significantly lower 
than the Kd of GDNF for its receptor. This would leave most GDNF receptors 
unoccupied, depriving SSCs and progenitor spermatogonia of the necessarily 
stimulus.  
We recognize that a reduction in GDNF expression in SCO testes, when 
viewed by itself, might not be viewed as proof of Sertoli cell dysfunction, but 
rather as a consequence of the loss of stimulus of Sertoli cells from 
spermatogenic cells. However, GDNF mRNA levels were not reduced in testes 
that had significantly reduced numbers of germ cells due to maturation arrest of 
spermatogenesis. We also recognized that decreased GDNF expression in the 
SCO testis might reflect an overall hypofunction of Sertoli cells and not a specific 
dysfunction. Thus, to distinguish between these two possibilities, we also 
quantified transcripts encoding two Sertoli cell products, kit ligand and clusterin. 
Expression of neither kit ligand mRNA nor clusterin were reduced in SCO testes, 
indicating that the SCO phenotype may be associated with a specific deficit in the 
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Sertoli cells. Taken together, our data suggest that a decrease in GDNF 
concentration in the fluid that bathes SSCs or progenitor spermatogonia is 
caused by a specific deficit in Sertoli cell function and is one probable cause for 
the diminished numbers and function of human SSCs associated with the clinical 
SCO phenotype.  
We also acknowledge that GDNF may not be the sole regulator of the 
numbers of these cells in humans, leading us to propose that other intrinsic or 
extrinsic factors act in concert with GDNF to regulate the numbers of SSCs and 
progenitor spermatogonia, and that some of these other growth factors may not 
be expressed in the SCO testis. Thus, a requirement for investigating growth 
factors as treatments of human male infertility must begin with the identification 
of a full repertoire of growth factors implicated in regulating the numbers, 
replication and differentiation of these cells.  
A comparison of GFRα1+ spermatogonia in fertile men, mice and rats: 
Using a mouse model, we have previously shown that GDNF regulates 
the numbers and replication of SSCs and progenitor spermatogonia, stimulates 
their expression of GFRα1 and suppresses their differentiation [9, 12]. If GDNF is 
the primary regulator of the numbers of SSCs and progenitor spermatogonia, 
then mice should have higher densities of GFRα1+ spermatogonia along the 
surface of their seminiferous tubules than rats and humans. However, this is not 
what we observed. Our data show that densities of GFRα1+ cells were highest in 
humans, intermediate in rat tubules and lowest in mouse tubules. The 
observation of dense GFRα1+ spermatogonia in human tubules is consistent with 
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the conclusion that humans have a much higher ratio of SSCs and progenitor 
spermatogonia vs. differentiated spermatogonia, than do rodents [7, 32]. 
However, we were surprised by the observation of long chains of GFRα1+ cells, 
which appeared to be connected, in both rats and humans. We consider these 
cells to function primarily as progenitor spermatogonia and analogous to Aal 
spermatogonia. Such long chains of GFRα1+ Aal spermatogonia are rarely 
observed in the mouse and do not normally exceed more than 4 cells in a chain 
[9, 12]. However, in mice, longer chains of Aal spermatogonia, comprising of 8 or 
16 cells, can be identified with the use of other markers. We have interpreted the 
lack of expression of GFRα1 in these longer chains as indicating that these cells 
have already initiated differentiation. Thus, longer chains of GFRα1 
spermatogonia in rats and humans may indicate that differentiation of SSCs 
and/or progenitor spermatogonia is suppressed for a longer period of time; even 
through GDNF concentration is higher in the mouse, when compared to the rat or 
the human.   
These differences also suggest the involvement of other intrinsic or 
extrinsic factors contributing to the regulation of the numbers or function of these 
SSCs in humans. This hypothesis is consistent with the fact that there are two 
different populations of SSCs in humans, a reserve and rarely dividing pool and 
an active population of SSCs that sustain normal spermatogenesis. The 
hypothesis that multiple growth factors regulate SSCs in vivo is also consistent 
with what is known about stem cells in many other tissues [33-35]. For instance, 
in bone marrow hematopoietic stem cells (HSCs), Wint3a and throbopoietin are 
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required for maintenance, while BMP and hedgehog signaling pathways promote 
self-renewal and long-term function, respectively [36, 37]. In addition, Notch 
signaling regulates formation of progenitors from HSCs, in specific blood cell 
lineages [32].  The regulation of hair follicles is even more complex because they 
contain two types of stem cells, which are regulated by different cytokines, and 
undergo mitosis at different times in the hair follicle cycle [6]. Given the complex 
biology of spermatogonial stem cells and progenitor spermatogonia, and the 
differences we have noted between humans and rodents, it is reasonable to 
conclude that multiple growth factors regulate the numbers, replication and 
differentiation of these cells. However, taken together, the results outlined in this 
chapter lead us to propose that GDNF does play a significant role in sustaining 
SSCs and progenitor spermatogonia in humans, as it does in mice.  
Evidence that GFRα1 identifies human spermatogonial stem cells and progenitor 
spermatogonia: 
Lastly, we were interested in confirming that the cells expressing GFRα1 
were SSCs and progenitor spermatogonia. One way to do this was to co-stain 
seminiferous tubules from fertile individuals with GFRα1 and UCHL1. Valli and 
colleagues have previously demonstrated that 92% of UCHL1+ human 
spermatogonia do not express the differentiation marker, Kit [6, 15, 38]. Based 
on their findings, we concluded that UCHL1 broadly identifies human SSCs and 
progenitor spermatogonia. Our results showed the same pattern of high and low 
density areas of UCHL1+ spermatogonia, as previously noted with GFRα1. In 
addition, we were able to visualize co-localization of spermatogonia in whole 
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mounts of seminiferous tubules, suggesting that some human spermatogonial 
stem cells and/or progenitor spermatogonia express the ligand binding subunit of 
the receptor needed to respond to GDNF. However, we acknowledge that the 
tubules analyzed come from one fertile individual, and that additional samples 
need to be analyzed quantitatively to account for the degree of overlap between 
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SUMMARY 
Glial cell line-derived neurotrophic factor (GDNF) has been shown to be 
expressed in the human testis, bringing to light the question of whether it is 
required for human male fertility and, whether it targets the same cell-types in 
humans, as it does in mice [13]. Our data strongly support the hypothesis that 
GDNF is an important regulator of human spermatogonial stem cells and 
progenitor spermatogonia and that an inadequate concentration of GDNF can 
lead to the loss of numbers and/or function of these cells. When viewed from a 
therapeutic perspective, our data suggest that increasing intratesticular levels of 
GDNF in these infertile men might increase SSC numbers and function. In turn, 
this could increase the possibility that sufficient sperm are generated for either 
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FIGURE LEGEND 
Figure 1. A comparison of GDNF mRNA concentration in testes of normal men 
and mice. Transcripts were quantified by digital PCR, and data (means + SEM; 
n=3 for mice and n=6 for humans) were normalized to 18S rRNA.  
Figure 2. GDNF protein levels in human and mouse serum. Overall, transcript 
levels in humans (n= 5) and mice (n=4) were undetectable because they were 
below the level of sensitivity of the assay. Data are presented as pg/ml 
concentrations. 
Figure 3. GDNF protein levels in the total testicular fluid of fertile men, rats and 
mice. Data (means +SEM; n=4 for humans and n=5 for rats and mice) are 
presented as pg/ml and pM of GDNF protein. For rats and mice, total testicular 
fluid was extracted from one testis per animal. In humans, total testicular fluid 
was collected from individuals undergoing vasectomy reversals. Statistical 
significance is identified by the different letters over the bars.  
Figure 4. GDNF protein levels in fertile rat seminiferous tubule fluid (STF), 
testicular interstitial fluid testis fluid (TIF), and total testis fluid (TTF). Data (means 
+ SEM; n=4) are presented as pg/ml and pM concentrations. Statistical 
significance is identified by the different letters over the bars.  
Table 1. Characterization of fertile and infertile men. 
Figure 5. A comparison of GDNF, DDX4, kit ligand (KL) and clusterin mRNA 
concentration in testes of fertile and infertile men. Numbers of transcripts 
encoding GDNF (means + SEM, N=6/group) (Fig. 7A), DDX4 (means + SEM, 
N=6-7/group) (Fig. 7B), KL (means + SEM, N=6-7/group) (Fig. 7C) and clusterin 
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(means + SEM; n=6/group) (Fig. 7D) were normalized to 18S rRNA. Bars with 
different letters represent statistical differences for each gene. 
Figure 6. Localization of GFRα1 spermatogonia in seminiferous tubule whole 
mounts of fertile men, mice and rats. Confocal images of human (A-C), mouse 
(D- F) and rat (G-I) whole mounts were taken at a 25X magnification. Figures A, 
D and G show a high density of GFRα1+ cells juxtaposed to images (B, E and H) 
of whole mounts with a lower density of GFRα1+ cells. Additional areas of these 
tubules were devoid of GFRα1+ spermatogonia, and these areas appeared no 
different from negative control tubules. Negative controls included the 
replacement of primary antibody with isotype control IgG (data not shown) or the 
exclusion of primary antibody (C, F and I). Edges of the seminiferous tubules are 
outlined in white lines. Edges of the seminiferous tubules are outlined in white 
lines.   
Figure 7. Quantification of the distribution of GFRα1+ spermatogonia in fertile 
mice and men. Percentage of the surface of human and mouse seminiferous 
tubules with a high, or no GFRα1+ cells were quantified. Data from tubules from 
three separate human and mouse testes are expressed as the mean + SEM of 
the area of the tubule.   
Figure 8. Localization of UCHL1+ spermatogonia in seminiferous tubule whole 
mounts of fertile men. Panel A shows an area of the tubule with lots of UCHL1+ 
spermatogonia (>25 cells per image), identified as an area of high density. Panel 
B shows an area of the tubule with a few UCHL1+ spermatogonia (1-25 cells per 
image), identified as an area of low density. Negative controls included the 
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replacement of primary antibody with isotype control IgG (panel C) or the 
exclusion of primary antibody (data not shown), and were identical to areas of the 
tubule where no UCHL1+ spermatogonia were identified. All images are 2.3 
micron thick optical sections of seminiferous tubule whole mounts, imaged using 
confocal microscopy.  
Figure 9. Co-localization of spermatogonia GFRα1+ and UCHL1+ spermatogonia 
in seminiferous tubule whole mounts of fertile men. Tubules were immunostained 
for both proteins and 2.3 micron thick optical sections were captured by confocal 
microscopy. Green (UCHL1) and red (GFRα1) channels were captured 
separately. Top panel: Results for expression of UCHL1 (A, F, J) alone, GFRα1 
(B,E,H,I) alone, and both proteins together (C,D,G) are shown. These images 
reveal considerable heterogeneity in the intensity of cellular expression of 
GFRα1and co-localization. While many cells express both proteins (See box in 
5C as well as D, E and F), some cells only express UCHL1 (See white arrow in 
C, and G & H), while others only express GFRα1 (See yellow arrow in C, and I & 
J). Bottom panel: The same image displayed in black and white. Brightness and 

















































































Y chromosome microdeletion 
26 
Cadaveric (Left 




testis) Complete spermatogenesis: spermatids count: 0-12 (Median 3) 
Not tested 
25 
Late MA Testis, right (biopsy): Spermatogenic arrest at secondary 
spermatocyte stage, with focal germ cell degeneration.  Mild 
peritubular fibrosis. Leydig cells unremarkable. In most tubules, the 
spermatogenic arrest is present at the primary spermatocyte stage, 
although a few secondary spermatocytes are present. Definitive 
spermatids were not identified. 
No Y chromosome microdeletions 
45 
Late MA Right testis biopsy: Late maturation arrest: Seminiferous tubules 
contain fairly normal numbers of spermatogonia that mature to the 
level of secondary spermatocytes. However, only occasional 
mature sperms are noted. Basement membranes are not thickened 
and normal numbers of Leydig cells are present in the interstitium. 
No Y chromosome microdeletions 
48 
Late MA Testis, right, biopsy: Spermatogenic arrest at secondary 
spermatocyte stage, see note. Leydig cells are unremarkable. 
Note: Degenerative germ cells are seen in some tubular lumina. 
There are structures which could possibly represent spermatids, 
but they are most likely to be degenerating pyknotic germ cell 
nuclei. Minimal peritubular fibrosis is seen. 
No Y chromosome microdeletions 
34 
SCO Testis, right (biopsy): Germ cell aplasia (Sertoli only pattern) is 
present in 100% of tubules. Leydig cells are present, 
unremarkable. 
No Y chromosome microdeletions 
27 
SCO Testis, right (biopsy): Germ cell aplasia (Sertoli cell only pattern). 
Sertoli cells only: 100% of tubules Leydig cells: Present, 
unremarkable 
No Y chromosome microdeletions 
40 
SCO Testis, left (biopsy): Sertoli-only testis, with mild peritubular fibrosis. 
Leydig cells, unremarkable. 
Not tested 
33 
SCO Testis, left (biopsy): Germ cell aplasia (Sertoli cell only pattern). 
Active spermatogenesis (complete maturation): 0% of tubules. 
Sertoli cell only pattern: 100% of tubules. Tubular atrophy: 10% of 
tubules Leydig cells: Present, unremarkable. 
No Y chromosome microdeletions 
49 
SCO Testis, right (biopsy): Germ cell aplasia (Sertoli only pattern) is 
present in 100% of tubules. Leydig cells are present. 
No Y chromosome microdeletions 
32 
SCO Testis, right, biopsy: Sertoli-only testis with moderate peritubular 
fibrosis. Leydig cells unremarkable. 
No Y chromosome microdeletions 
29 
MA Spermatogenic arrest at primary spermatocyte stage, with rare 
secondary spermatocytes. Peritubular fibrosis, moderate. Leydig 
cells, unremarkable. 
No Y chromosome microdeletions 
46 
MA Testis, right, biopsy: Azoospermia. Maturation arrest (primary 
spermatocyte): 60% of tubules. Maturation arrest (secondary 
spermatocyte): 30% of tubules. Leydig cells: Present, 
unremarkable. Intratubular germ cell neoplasia: Absent. Peritubular 
fibrosis: Present, mild Inflammation. 
No Y chromosome microdeletions 
37 
MA Testis, right (biopsy): Maturation arrest. Maturation arrest (primary 
spermatocyte): 100% of tubules. Leydig cells: Present, 
unremarkable. Intratubular germ cell neoplasia: Absent. Peritubular 
fibrosis: Absent. Inflammation: Absent. Note: Although the biopsy 
shows uniform arrest at the primary spermatocyte, increased 
numbers of giant spermatogonia (without atypia) are noted the 
presence of which has been associated with a "mixed atrophy" 
picture [Sigg C and Hedinger C. Virchows Arch. (1983)]. 
No Y chromosome microdeletions 
40 
Cadaveric (Right 
testis) Complete spermatogenesis 
Not tested 













testis) Complete spermatogenesis 
Not tested 
24 
SCO Testis, right (biopsy): Germ cell aplasia (Sertoli cell only pattern) in 
100% of tubules. Leydig cells: Present, unremarkable. Intratubular 




SCO Testis, right (biopsy): Germ cell aplasia (Sertoli cell only pattern), 
Sertoli cells only: 100% of tubules. Leydig cells: Present, 
unremarkable. Intratubular germ cell neoplasia: Absent. Peritubular 
fibrosis/hyalinization: Focal, mild. Inflammation: Absent. 
No Y chromosome microdeletions 
27 
SCO Testis, right (biopsy): Germ cell aplasia (Sertoli cell only pattern), 
present in 100% of tubules. Leydig cells:  Present, unremarkable. 
Intratubular germ cell neoplasia: Absent. Peritubular fibrosis: 
Present. Inflammation: Absent. 
No Y chromosome microdeletions 
33 
SCO Testis, right (biopsy): Germ cell aplasia (Sertoli cell only pattern) in 
100% of tubules. Leydig cells: Present, increased. Intratubular 




MA Testis, right (biopsy): Severe hypospermatogenesis. Maturation 
arrest (primary spermatocyte): 95% of tubules. Tubular atrophy: 
5% of tubules. Leydig cells: Present, unremarkable. Intratubular 
germ cell neoplasia: Absent. Peritubular fibrosis: Absent. 
Inflammation: Absent. 
No Y chromosome microdeletions 
34 
MA Testis, right (biopsy): Maturation Arrest. Maturation arrest (primary 
spermatocyte): 90% of tubules. Maturation arrest (germ cell): 5% of 
tubules. Tubular atrophy: 5% of tubules. Leydig cells: Present, 
unremarkable. Intratubular germ cell neoplasia: Absent. Peritubular 
fibrosis: Absent. Inflammation: Absent. 
No Y chromosome microdeletions 
34 
MA93%/SCO2% Testis, left (biopsy): Maturation arrest (primary spermatocyte): 93% 
of tubules. Sertoli cells only: 2% of tubules. Tubular atrophy: 5% of 
tubules. Leydig cells: Present, unremarkable. Intratubular germ cell 
neoplasia: Absent (OCT-4 immunostain is negative). Peritubular 
fibrosis: Present, moderate. Inflammation: Absent. 
No Y chromosome microdeletions 
40 
MA Testis, right (biopsy): Maturation arrest. Maturation arrest (primary 
spermatocyte): 100% of tubules. Leydig cells: Present, 
unremarkable. Intratubular germ cell neoplasia: Absent. Peritubular 
fibrosis: Absent. Inflammation: Absent. 
No Y chromosome microdeletions 
40 Cadaveric Complete spermatogenesis Not tested 
40 Cadaveric Complete spermatogenesis Not tested 
40 Cadaveric Complete spermatogenesis Not tested 
25 Cadaveric Complete spermatogenesis Not tested 
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CHAPTER 4: CONCLUSIONS 
Introduction: 
Male fertility hinges on the delicate balance between re-newel of stem 
cells and their proliferation and differentiation, a balance necessary for 
maintaining the stem cell pool and supporting spermatogenesis. The growth 
factor glial cell line-derived neurotrophic factor (GDNF) has been shown to be 
critical in regulating this balance in the prepubertal mouse, but its in vivo function 
in the normal adult mouse testis has never been directly studied. Filling this gap 
in our knowledge becomes particularly important when we consider the fact that 
the mouse is a representative model for investigating spermatogenesis in 
humans. However, in spite of significant overlap in similarities between species, 
we acknowledge the presences of subtle differences. In order to overcome these 
differences, we used testicular tissue biopsies to directly study the effects of 
GDNF in fertile and infertile men. The findings from our results provide significant 
support for the hypothesis that in humans, GDNF is essential for maintaining the 
pool of spermatogonial stem cells, as it is in mice.  
The role of GDNF in regulating stem and progenitor spermatogonia in vivo in the 
normal adult mouse testis: 
Using a unique in vivo chemical-genetic approach, we were able to 
investigate the effects of inhibition of the GDNF signaling complex on stem and 
progenitor spermatogonia in the normal adult mouse testes. We were the first to 
use this approach to investigate the direct regulation of any adult stem cell 
population by a single growth factor. There were three advantages to this 
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experimental strategy: 1) it involved a completely normal pool of stem cells, 2) we 
could analyze the in vivo response of stem cells to acute and prolonged changes 
in signaling from a specific growth factor, and 3) the inhibition was reversible. Our 
results demonstrate that inhibiting the GDNF signaling  complex for varying 
periods of time causes a sequential loss of stem cells as identified by the SSC 
markers: Ret, GFRα1 and Zbtb16, respectively. We also show that SSCs and 
progenitor spermatogonia respond to this loss differently; where some of these 
cells are lost when the GDNF signaling complex is inhibited for only 2 days, while 
others persist for up to 11 days. We thought that this loss of cells would be 
marked by an increase in apoptosis. Surprisingly, we observed no such increase. 
Thus, we propose that this loss occurs because the SSCs fail to re-new, and 
instead preferentially differentiate into type A1 spermatogonia; a hypothesis 
consistent with the current model in the field (Figure 1). Taken together, these 
data provide evidence in support of the hypothesis that GDNF is essential in 
regulating the self-renewal and differentiation of SSC and progenitor 
spermatogonia in the normal mature mouse testis.  
The role of GDNF in regulating spermatogenesis in fertile and infertile men:  
Glial cell line-derived neurotrophic factor (GDNF) has been shown to be 
expressed in the human testis. However, the question remains as to whether it is 
required for human male fertility and, whether it targets the same cell-types in 
humans, as it does in mice. Our data strongly support the hypothesis that GDNF 
is an important regulator of human spermatogonial stem cells and progenitor 
spermatogonia, and that an inadequate concentration GDNF can lead to the loss 
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of numbers and/or function of these cells. Our motivation to pursue translational 
studies stemmed from the surprising similarity between the histology of Ret 
(V805A) mice injected with NA-PP1 for 30 days and what clinicians were 
reporting in their Sertoli cell-only patients. In both cases, the seminiferous tubules 
were devoid of almost all germ cells, while primarily retaining Sertoli cells lining 
the rim of the tubule. The long-term goal of our research is to be able to alleviate 
some of the fertility challenges these individuals face, and in turn, improving their 
quality of life.  
Our translational work began with the comparison and observation that 
GDNF mRNA levels were almost identical in human and mouse testes. This 
motivated us to compare GDNF protein concentrations in the testicular fluids of 
humans, mice and rats. Results showed that the concentration of GDNF in 
human total testicular fluid is almost identical to its concentration in rat total 
testicular fluid; suggesting that as in rodents, the concentration of GDNF 
surrounding human SSCs is sufficient to act as a mitogen and cell survival factor 
for these stem cells. Based on this similarity, we extrapolated relationships 
between fluids in the rat as a model to understand the consequences of GDNF 
protein levels on SSCs and progenitor spermatogonia in humans. These 
assumptions allowed us to estimate that the concentration of GDNF in the 
testicular interstitial fluid (TIF) of a fertile man is 31% of its concentration in the 
total testicular fluid. This becomes particularly important because it predicts that 
the 80% decrease in expression of GDNF mRNA in the human SCO testis 
translates to a GDNF concentration of ~2pM in the TIF of these infertile men, a 
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concentration much lower than the Kd of GDNF for its receptor, GFRα1. Such a 
low concentration would leave most GDNF receptors unoccupied, depriving 
SSCs and progenitor spermatogonia of the stimulus necessary to maintain the 
stem cell pool and sustain spermatogenesis. To distinguish between the 
possibility of whether decreased GDNF expression in the Sertoli cell-only (SCO) 
testis was due to an overall hypo-function or a specific dysfunction of Sertoli 
cells, we quantified transcripts encoding two Sertoli cell products, kit ligand and 
clusterin. Expression of neither kit ligand mRNA nor clusterin were reduced in 
SCO testes, indicating that the SCO phenotype may be associated with a 
specific deficit in Sertoli cell function. Taken together, these data provide a 
potential explanation for the diminished numbers and function of human SSCs 
associated with the clinical SCO phenotype.  
Conclusions and future directions: 
The impact of this research really resonates when viewed from a clinical 
and therapeutic perspective. Our data suggest that increasing intratesticular 
levels of GDNF in these SCO men might increase SSC numbers and function, 
and increase that possibility that sufficient sperm are generated for either natural 
or assisted conception. Focal areas of spermatogenesis, which can be found in 
SCO individuals, would be the main targets of such an approach. Figure 2 shows 
such a scenario, where a seminiferous tubule with normal spermatogenesis 
(lower right) is surround by tubules that are otherwise Sertoli cell-only. The 
objective would be to stimulate the few remaining SSCs and progenitor 
spermatogonia to re-new and differentiate into sperm, by exposing these cells to 
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elevated GDNF concentrations. This, in turn, could increase the success rates 
and efficiency of sperm retrieval through micro-TESE surgeries. However, we 
acknowledge that stem cell regulation is a complex process, requiring several 
growth factors to work in concert. Thus, the first prerequisite to such a 
therapeutic approach would require a thorough understanding of all other factors 
involved. Then, it would be worth measuring the message and protein levels of 
the top candidate growth factors that are common in fertile and infertile men 
using digital PCR/RT-PCR and ELISA, respectively. These data would help to 
get a sense of which growths factors are up or down regulated in infertile 
individuals. To test if these growth factors regulate the behavior and numbers of 
SSCs and progenitor spermatogonia, we can culture alginate encapsulated 
seminiferous tubules from fertile men, in the presence of individual growth factors 
at varying concentrations. Previous in vitro studies in the lab have shown that 
when isolated seminiferous tubules from fertile mice were cultured in the 
presence of a physiologically relevant concentration of recombinant GDNF (250 
pg/ml or 21.6 pM), we observed an increase in replication of As, Apr, and Aal 
spermatogonia. These in vitro results mimic our in vivo results, and are in 
agreement with the hypothesis stating that GDNF regulates SSCs and progenitor 
spermatogonia. To test whether these growth factors work in a cooperative 
fashion, we can culture these tubules in the presence of different combinations 
and concentrations of candidate growth factors. Based on which combinations 
yield replication of SSC and progenitor spermatogonia, we will know which 
growths factors should be considered for therapy and get a sense of their 
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effective concentrations. Moving forward, we acknowledge that tittering 
concentrations is extremely important. We have previously observed the 
formation of clusters of stem and progenitor spermatogonia in the mouse, when 
the seminiferous tubules were exposed to higher concentrations of GDNF. Thus, 
to prevent the potential formation of tumorigenic clusters, we must be cautious of 
the concentrations. From here, we will have to test the selected growth factors at 
their respective concentrations in vivo. One approach would involve using a 
mouse model, where we could surgically attach a slow release device containing 
these growth factors to the testes. The ideal mouse model would mimic the SCO 
phenotype, where we could also find the presence of focal areas with active 
spermatogenesis. If a specific mouse model is not available, we could also 
induce a SCO like state in our Ret (V805A) mice using NA-PP1. The goal would 
be to observe an improvement or restoration in spermatogenesis. If we could 
achieve this in vivo, then we would have the preliminary data to start entertaining 
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FIGURE LEGEND 
Figure 1.  The current model in the field suggests that under low concentration of 
GDNF, SSCs preferentially self- renew. Conversly, when exposed to high 
concentratinos of GDNF, these cells move towards differentiation.  
Figure 2. Testicular cross- section (x400) showing a seminiferous tubule with 
normal spermatogenesis (lower right) surround by tubules that are otherwise 
Sertoli cell-only. Adapted from Silber, S.J., et al., Round spermatid injection. 
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